 Mr. Speaker, I move to suspend the rules and pass the  bill (H.R. 7328) to reauthorize certain programs under the Public  Health Service Act and the Federal Food, Drug, and Cosmetic Act with  respect to public health security and all-hazards preparedness and  response, to clarify the regulatory framework with respect to certain  nonprescription drugs that are marketed without an approved drug  application, and for other purposes.   The Clerk read the title of the bill.   The text of the bill is as follows:                                 H.R. 7328         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE; TABLE OF CONTENTS.         (a) Short Title.--This Act may be cited as the ``Pandemic       and All-Hazards Preparedness and Advancing Innovation Act of       2018''.        (b) Table of Contents.--The table of contents for this Act       is as follows:  Sec. 1. Short title; table of contents.      DIVISION A--PANDEMIC AND ALL-HAZARDS PREPAREDNESS AND ADVANCING                                 INNOVATION  Sec. 100. References in division.        TITLE I--STRENGTHENING THE NATIONAL HEALTH SECURITY STRATEGY  Sec. 101. National Health Security Strategy.               TITLE II--IMPROVING PREPAREDNESS AND RESPONSE  Sec. 201. Improving benchmarks and standards for preparedness and                response. Sec. 202. Amendments to preparedness and response programs. Sec. 203. Regional health care emergency preparedness and response                systems. Sec. 204. Military and civilian partnership for trauma readiness. Sec. 205. Public health and health care system situational awareness                and biosurveillance capabilities. Sec. 206. Strengthening and supporting the public health emergency                rapid response fund. Sec. 207. Improving all-hazards preparedness and response by public                health emergency volunteers. Sec. 208. Clarifying State liability law for volunteer health care                professionals. Sec. 209. Report on adequate national blood supply. Sec. 210. Report on the public health preparedness and response                capabilities and capacities of hospitals, long-term care                facilities, and other health care facilities.                    TITLE III--REACHING ALL COMMUNITIES  Sec. 301. Strengthening and assessing the emergency response workforce. Sec. 302. Health system infrastructure to improve preparedness and                response. Sec. 303. Considerations for at-risk individuals. Sec. 304. Improving emergency preparedness and response considerations                for children. Sec. 305. National advisory committees on disasters. Sec. 306. Guidance for participation in exercises and drills.               TITLE IV--PRIORITIZING A THREAT-BASED APPROACH  Sec. 401. Assistant Secretary for Preparedness and Response. Sec. 402. Public Health Emergency Medical Countermeasures Enterprise. Sec. 403. Strategic National Stockpile. Sec. 404. Preparing for pandemic influenza, antimicrobial resistance,                and other significant threats. Sec. 405. Reporting on the Federal Select Agent Program.   TITLE V--INCREASING COMMUNICATION IN MEDICAL COUNTERMEASURE ADVANCED                          RESEARCH AND DEVELOPMENT  Sec. 501. Medical countermeasure budget plan. Sec. 502. Material threat and medical countermeasure notifications. Sec. 503. Availability of regulatory management plans. Sec. 504. The Biomedical Advanced Research and Development Authority                and the BioShield Special Reserve Fund. Sec. 505. Additional strategies for combating antibiotic resistance.        TITLE VI--ADVANCING TECHNOLOGIES FOR MEDICAL COUNTERMEASURES  Sec. 601. Administration of countermeasures. Sec. 602. Updating definitions of other transactions. Sec. 603. Medical countermeasure master files. Sec. 604. Animal rule report. Sec. 605. Review of the benefits of genomic engineering technologies                and their potential role in national security. Sec. 606. Report on vaccines development. Sec. 607. Strengthening mosquito abatement for safety and health.                    TITLE VII--MISCELLANEOUS PROVISIONS  Sec. 701. Reauthorizations and extensions. Sec. 702. Location of materials in the stockpile. Sec. 703. Cybersecurity. Sec. 704. Strategy and report. Sec. 705. Technical amendments.   DIVISION B--OVER-THE-COUNTER MONOGRAPH SAFETY, INNOVATION, AND REFORM  Sec. 1000. Short title; references in division.                          TITLE I--OTC DRUG REVIEW  Sec. 1001. Regulation of certain nonprescription drugs that are                marketed without an approved drug application. Sec. 1002. Misbranding. Sec. 1003. Drugs excluded from the over-the-counter drug review. Sec. 1004. Treatment of Sunscreen Innovation Act. Sec. 1005. Annual update to Congress on appropriate pediatric                indication for certain OTC cough and cold drugs. Sec. 1006. Technical corrections.                            TITLE II--USER FEES  Sec. 2001. Short title; finding. Sec. 2002. Fees relating to over-the-counter drugs.      DIVISION A--PANDEMIC AND ALL-HAZARDS PREPAREDNESS AND ADVANCING                                 INNOVATION       SEC. 100. REFERENCES IN DIVISION.         Except as otherwise specified--        (1) amendments made by this division to a section or other       provision of law are amendments to such section or other       provision of the Public Health Service Act (42 U.S.C. 201 et       seq.); and        (2) any reference to ``this Act'' contained in this       division shall be treated as referring only to the provisions       of this division.        TITLE I--STRENGTHENING THE NATIONAL HEALTH SECURITY STRATEGY       SEC. 101. NATIONAL HEALTH SECURITY STRATEGY.         Section 2802 (42 U.S.C. 300hh-1) is amended--        (1) in subsection (a)--        (A) in paragraph (1)--        (i) by striking ``2014'' and inserting ``2018''; and        (ii) by striking the second sentence and inserting the       following: ``Such National Health Security Strategy shall       describe potential emergency health security threats and       identify the process for achieving the preparedness goals       described in subsection (b) to be prepared to identify and       respond to such threats and shall be consistent with the       national preparedness goal (as described in section       504(a)(19) of the Homeland Security Act of 2002), the       National Incident Management System (as defined in section       501(7) of such Act), and the National Response Plan developed       pursuant to section 504 of such Act, or any successor       plan.'';        (B) in paragraph (2), by inserting before the period at the       end of the second sentence the following: ``, and an analysis       of any changes to the evidence-based benchmarks and objective       standards under sections 319C-1 and 319C-2''; and        (C) in paragraph (3)--        (i) by striking ``2009'' and inserting ``2022'';        (ii) by inserting ``(including gaps in the environmental       health and animal health workforces, as applicable),       describing the status of such workforce'' after ``gaps in       such workforce'';        (iii) by striking ``and identifying strategies'' and       inserting ``identifying strategies''; and        (iv) by inserting before the period at the end ``, and       identifying current capabilities to meet the requirements of       section 2803''; and        (2) in subsection (b)--        (A) in paragraph (2)--        (i) in subparagraph (A), by striking ``and investigation''       and inserting ``investigation, and related information       technology activities'';        (ii) in subparagraph (B), by striking ``and       decontamination'' and inserting ``decontamination, relevant       health care services and supplies, and transportation and       disposal of medical waste''; and        (iii) by adding at the end the following:        ``(E) Response to environmental hazards.'';        (B) in paragraph (3)--        (i) in the matter preceding subparagraph (A), by striking       ``including mental health''  [[Page H10367]]       and inserting ``including pharmacies, mental health       facilities,''; and        (ii) in subparagraph (F), by inserting ``or exposures to       agents that could cause a public health emergency'' before       the period;        (C) in paragraph (5), by inserting ``and other applicable       compacts'' after ``Compact''; and        (D) by adding at the end the following:        ``(9) Zoonotic disease, food, and agriculture.--Improving       coordination among Federal, State, local, tribal, and       territorial entities (including through consultation with the       Secretary of Agriculture) to prevent, detect, and respond to       outbreaks of plant or animal disease (including zoonotic       disease) that could compromise national security resulting       from a deliberate attack, a naturally occurring threat, the       intentional adulteration of food, or other public health       threats, taking into account interactions between animal       health, human health, and animals' and humans' shared       environment as directly related to public health emergency       preparedness and response capabilities, as applicable.        ``(10) Global health security.--Assessing current or       potential health security threats from abroad to inform       domestic public health preparedness and response       capabilities.''.               TITLE II--IMPROVING PREPAREDNESS AND RESPONSE       SEC. 201. IMPROVING BENCHMARKS AND STANDARDS FOR PREPAREDNESS                     AND RESPONSE.         (a) Evaluating Measurable Evidence-based Benchmarks and       Objective Standards.--Section 319C-1 (42 U.S.C. 247d-3a) is       amended by inserting after subsection (j) the following:        ``(k) Evaluation.--        ``(1) In general.--Not later than 2 years after the date of       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018 and every 2 years       thereafter, the Secretary shall conduct an evaluation of the       evidence-based benchmarks and objective standards required       under subsection (g). Such evaluation shall be submitted to       the congressional committees of jurisdiction together with       the National Health Security Strategy under section 2802, at       such time as such strategy is submitted.        ``(2) Content.--The evaluation under this paragraph shall       include--        ``(A) a review of evidence-based benchmarks and objective       standards, and associated metrics and targets;        ``(B) a discussion of changes to any evidence-based       benchmarks and objective standards, and the effect of such       changes on the ability to track whether entities are meeting       or making progress toward the goals under this section and,       to the extent practicable, the applicable goals of the       National Health Security Strategy under section 2802;        ``(C) a description of amounts received by eligible       entities described in subsection (b) and section 319C-2(b),       and amounts received by subrecipients and the effect of such       funding on meeting evidence-based benchmarks and objective       standards; and        ``(D) recommendations, as applicable and appropriate, to       improve evidence-based benchmarks and objective standards to       more accurately assess the ability of entities receiving       awards under this section to better achieve the goals under       this section and section 2802.''.        (b) Evaluating the Partnership for State and Regional       Hospital Preparedness.--Section 319C-2(i)(1) (42 U.S.C. 247-      3b(i)(1)) is amended by striking ``section 319C-1(g), (i),       and (j)'' and inserting ``section 319C-1(g), (i), (j), and       (k)''.       SEC. 202. AMENDMENTS TO PREPAREDNESS AND RESPONSE PROGRAMS.         (a) Cooperative Agreement Applications for Improving State       and Local Public Health Security.--Section 319C-1 (42 U.S.C.       247d-3a) is amended--        (1) in subsection (a), by inserting ``, acting through the       Director of the Centers for Disease Control and Prevention,''       after ``the Secretary''; and        (2) in subsection (b)(2)(A)--        (A) in clause (vi), by inserting ``, including public       health agencies with specific expertise that may be relevant       to public health security, such as environmental health       agencies,'' after ``stakeholders'';        (B) by redesignating clauses (vii) through (ix) as clauses       (viii) through (x);        (C) by inserting after clause (vi) the following:        ``(vii) a description of how, as applicable, such entity       may integrate information to account for individuals with       behavioral health needs following a public health       emergency;'';        (D) in clause (ix), as so redesignated, by striking ``;       and'' and inserting a semicolon; and        (E) by adding at the end the following:        ``(xi) a description of how the entity will partner with       health care facilities, including hospitals and nursing homes       and other long-term care facilities, to promote and improve       public health preparedness and response; and        ``(xii) a description of how, as appropriate and       practicable, the entity will include critical infrastructure       partners, such as utility companies within the entity's       jurisdiction, in planning pursuant to this subparagraph to       help ensure that critical infrastructure will remain       functioning during, or return to function as soon as       practicable after, a public health emergency;''.        (b) Exception Relating to Application of Certain       Requirements.--        (1) In general.--Section 319C-1(g) (42 U.S.C. 247d-3a(g))       is amended--        (A) in paragraph (5)--        (i) in the matter preceding subparagraph (A), by striking       ``Beginning with fiscal year 2009'' and inserting ``Beginning       with fiscal year 2019''; and        (ii) in subparagraph (A)--         (I) by striking ``for the immediately preceding fiscal       year'' and inserting ``for either of the 2 immediately       preceding fiscal years''; and        (II) by striking ``2008'' and inserting ``2018''; and         (B) in paragraph (6), by amending subparagraph (A) to read       as follows:        ``(A) In general.--The amounts described in this paragraph       are the following amounts that are payable to an entity for       activities described in this section or section 319C-2:        ``(i) For no more than 1 of each of the first 2 fiscal       years immediately following a fiscal year in which an entity       experienced a failure described in subparagraph (A) or (B) of       paragraph (5), an amount equal to 10 percent of the amount       the entity was eligible to receive for the respective fiscal       year.        ``(ii) For no more than 1 of the first 2 fiscal years       immediately following the third consecutive fiscal year in       which an entity experienced such a failure, in lieu of       applying clause (i), an amount equal to 15 percent of the       amount the entity was eligible to receive for the respective       fiscal year.''.        (2) Effective date.--The amendments made by paragraph (1)       shall apply with respect to cooperative agreements awarded on       or after the date of enactment of this Act.        (c) Partnership for State and Regional Hospital       Preparedness to Improve Surge Capacity.--Section 319C-2 (42       U.S.C. 247d-3b) is amended--        (1) in subsection (a)--        (A) by inserting ``, acting through the Assistant Secretary       for Preparedness and Response,'' after ``The Secretary''; and        (B) by striking ``preparedness for public health       emergencies'' and inserting ``preparedness for, and response       to, public health emergencies in accordance with subsection       (c)'';        (2) in subsection (b)(1)(A)--        (A) by striking ``partnership consisting of'' and inserting       ``coalition that includes'';        (B) in clause (ii), by striking ``; and'' and inserting a       semicolon; and        (C) by adding at the end the following:        ``(iv) one or more emergency medical service organizations       or emergency management organizations; and'';        (3) in subsection (d)--        (A) in paragraph (1)(B), by striking ``partnership'' each       place it appears and inserting ``coalition''; and        (B) in paragraph (2)(C), by striking ``medical       preparedness'' and inserting ``preparedness and response'';        (4) in subsection (f), by striking ``partnership'' and       inserting ``coalition'';        (5) in subsection (g)(2)--        (A) by striking ``Partnerships'' and inserting       ``Coalitions'';        (B) by striking ``partnerships'' and inserting       ``coalitions''; and        (C) by inserting ``and response'' after ``preparedness'';       and        (6) in subsection (i)(1)--        (A) by striking ``An entity'' and inserting ``A       coalition''; and        (B) by striking ``such partnership'' and inserting ``such       coalition''.        (d) Public Health Security Grants Authorization of       Appropriations.--Section 319C-1(h)(1)(A) (42 U.S.C. 247d-      3a(h)(1)(A)) is amended by striking ``$641,900,000 for fiscal       year 2014'' and all that follows through the period at the       end and inserting ``$685,000,000 for each of fiscal years       2019 through 2023 for awards pursuant to paragraph (3)       (subject to the authority of the Secretary to make awards       pursuant to paragraphs (4) and (5)).''.        (e) Partnership for State and Regional Hospital       Preparedness Authorization of Appropriations.--Section 319C-      2(j) (42 U.S.C. 247d-3b(j)) is amended--        (1) by amending paragraph (1) to read as follows:        ``(1) In general.--        ``(A) Authorization of appropriations.--For purposes of       carrying out this section and section 319C-3, in accordance       with subparagraph (B), there is authorized to be appropriated       $385,000,000 for each of fiscal years 2019 through 2023.        ``(B) Reservation of amounts for regional systems.--        ``(i) In general.--Subject to clause (ii), of the amount       appropriated under subparagraph (A) for a fiscal year, the       Secretary may reserve up to 5 percent for the purpose of       carrying out section 319C-3.        ``(ii) Reservation contingent on continued appropriations       for this section.--If for fiscal year 2019 or a subsequent       fiscal year, the amount appropriated under subparagraph (A)       is such that, after application of clause (i), the amount       remaining for the purpose of carrying out this section would       be less than the amount available for such purpose for the       previous fiscal year, the amount that may be reserved under       clause (i) shall be reduced such that the amount remaining       for the purpose of carrying out this section is not less than       the amount available for such purpose for the previous fiscal       year.        ``(iii) Sunset.--The authority to reserve amounts under       clause (i) shall expire on September 30, 2023.'';        (2) in paragraph (2), by striking ``paragraph (1) for a       fiscal year'' and inserting ``paragraph (1)(A) for a fiscal       year and not reserved  [[Page H10368]]       for the purpose described in paragraph (1)(B)(i)''; and        (3) in paragraph (3)(A), by striking ``paragraph (1) and       not reserved under paragraph (2)'' and inserting ``paragraph       (1)(A) and not reserved under paragraph (1)(B)(i) or (2)''.       SEC. 203. REGIONAL HEALTH CARE EMERGENCY PREPAREDNESS AND                     RESPONSE SYSTEMS.         (a) In General.--Part B of title III (42 U.S.C. 243 et       seq.) is amended by inserting after section 319C-2 the       following:       ``SEC. 319C-3. GUIDELINES FOR REGIONAL HEALTH CARE EMERGENCY                     PREPAREDNESS AND RESPONSE SYSTEMS.         ``(a) Purpose.--It is the purpose of this section to       identify and provide guidelines for regional systems of       hospitals, health care facilities, and other public and       private sector entities, with varying levels of capability to       treat patients and increase medical surge capacity during, in       advance of, and immediately following a public health       emergency, including threats posed by one or more chemical,       biological, radiological, or nuclear agents, including       emerging infectious diseases.        ``(b) Guidelines.--The Assistant Secretary for Preparedness       and Response, in consultation with the Director of the       Centers for Disease Control and Prevention, the Administrator       of the Centers for Medicare & Medicaid Services, the       Administrator of the Health Resources and Services       Administration, the Commissioner of Food and Drugs, the       Assistant Secretary for Mental Health and Substance Use, the       Assistant Secretary of Labor for Occupational Safety and       Health, the Secretary of Veterans Affairs, the heads of such       other Federal agencies as the Secretary determines to be       appropriate, and State, local, tribal, and territorial public       health officials, shall, not later than 2 years after the       date of enactment of this section--        ``(1) identify and develop a set of guidelines relating to       practices and protocols for all-hazards public health       emergency preparedness and response for hospitals and health       care facilities to provide appropriate patient care during,       in advance of, or immediately following, a public health       emergency, resulting from one or more chemical, biological,       radiological, or nuclear agents, including emerging       infectious diseases (which may include existing practices,       such as trauma care and medical surge capacity and       capabilities), with respect to--        ``(A) a regional approach to identifying hospitals and       health care facilities based on varying capabilities and       capacity to treat patients affected by such emergency,       including--        ``(i) the manner in which the system will coordinate with       and integrate the partnerships and health care coalitions       established under section 319C-2(b); and        ``(ii) informing and educating appropriate first responders       and health care supply chain partners of the regional       emergency preparedness and response capabilities and medical       surge capacity of such hospitals and health care facilities       in the community;        ``(B) physical and technological infrastructure, laboratory       capacity, staffing, blood supply, and other supply chain       needs, taking into account resiliency, geographic       considerations, and rural considerations;        ``(C) protocols or best practices for the safety and       personal protection of workers who handle human remains and       health care workers (including with respect to protective       equipment and supplies, waste management processes, and       decontamination), sharing of specialized experience among the       health care workforce, behavioral health, psychological       resilience, and training of the workforce, as applicable;        ``(D) in a manner that allows for disease containment       (within the meaning of section 2802(b)(2)(B)), coordinated       medical triage, treatment, and transportation of patients,       based on patient medical need (including patients in rural       areas), to the appropriate hospitals or health care       facilities within the regional system or, as applicable and       appropriate, between systems in different States or regions;       and        ``(E) the needs of children and other at-risk individuals;        ``(2) make such guidelines available on the internet       website of the Department of Health and Human Services in a       manner that does not compromise national security; and        ``(3) update such guidelines as appropriate, including       based on input received pursuant to subsections (c) and (e)       and information resulting from applicable reports required       under the Pandemic and All-Hazards Preparedness and Advancing       Innovation Act of 2018 (including any amendments made by such       Act), to address new and emerging public health threats.        ``(c) Considerations.--In identifying, developing, and       updating guidelines under subsection (b), the Assistant       Secretary for Preparedness and Response shall--        ``(1) include input from hospitals and health care       facilities (including health care coalitions under section       319C-2), State, local, tribal, and territorial public health       departments, and health care or subject matter experts       (including experts with relevant expertise in chemical,       biological, radiological, or nuclear threats, including       emerging infectious diseases), as the Assistant Secretary       determines appropriate, to meet the goals under section       2802(b)(3);        ``(2) consult and engage with appropriate health care       providers and professionals, including physicians, nurses,       first responders, health care facilities (including       hospitals, primary care clinics, community health centers,       mental health facilities, ambulatory care facilities, and       dental health facilities), pharmacies, emergency medical       providers, trauma care providers, environmental health       agencies, public health laboratories, poison control centers,       blood banks, tissue banks, and other experts that the       Assistant Secretary determines appropriate, to meet the goals       under section 2802(b)(3);        ``(3) consider feedback related to financial implications       for hospitals, health care facilities, public health       agencies, laboratories, blood banks, tissue banks, and other       entities engaged in regional preparedness planning to       implement and follow such guidelines, as applicable; and        ``(4) consider financial requirements and potential       incentives for entities to prepare for, and respond to,       public health emergencies as part of the regional health care       emergency preparedness and response system.        ``(d) Technical Assistance.--The Assistant Secretary for       Preparedness and Response, in consultation with the Director       of the Centers for Disease Control and Prevention and the       Assistant Secretary of Labor for Occupational Safety and       Health, may provide technical assistance and consultation       toward meeting the guidelines described in subsection (b).        ``(e) Demonstration Project for Regional Health Care       Preparedness and Response Systems.--        ``(1) In general.--The Assistant Secretary for Preparedness       and Response may establish a demonstration project pursuant       to the development and implementation of guidelines under       subsection (b) to award grants to improve medical surge       capacity for all hazards, build and integrate regional       medical response capabilities, improve specialty care       expertise for all-hazards response, and coordinate medical       preparedness and response across State, local, tribal,       territorial, and regional jurisdictions.        ``(2) Sunset.--The authority under this subsection shall       expire on September 30, 2023.''.        (b) GAO Report to Congress.--        (1) Report.--Not later than 3 years after the date of       enactment of this Act, the Comptroller General of the United       States (referred to in this subsection as the ``Comptroller       General'') shall submit to the Committee on Health,       Education, Labor, and Pensions and the Committee on Finance       of the Senate and the Committee on Energy and Commerce and       the Committee on Ways and Means of the House of       Representatives, a report on the extent to which hospitals       and health care facilities have implemented the recommended       guidelines under section 319C-3(b) of the Public Health       Service Act (as added by subsection (a)), including an       analysis and evaluation of any challenges hospitals or health       care facilities experienced in implementing such guidelines.        (2) Content.--The Comptroller General shall include in the       report under paragraph (1)--        (A) data on the preparedness and response capabilities that       have been informed by the guidelines under section 319C-3(b)       of the Public Health Service Act to improve regional       emergency health care preparedness and response capability,       including hospital and health care facility capacity and       medical surge capabilities to prepare for, and respond to,       public health emergencies; and        (B) recommendations to reduce gaps in incentives for       regional health partners, including hospitals and health care       facilities, to improve capacity and medical surge       capabilities to prepare for, and respond to, public health       emergencies, consistent with subsection (a), which may       include consideration of facilities participating in programs       under section 319C-2 of the Public Health Service Act (42       U.S.C. 247d-3b) or in programs under the Centers for Medicare       & Medicaid Services (including innovative health care       delivery and payment models), and input from private sector       financial institutions.        (3) Consultation.--In carrying out paragraphs (1) and (2),       the Comptroller General shall consult with the heads of       appropriate Federal agencies, including--        (A) the Assistant Secretary for Preparedness and Response;        (B) the Director of the Centers for Disease Control and       Prevention;        (C) the Administrator of the Centers for Medicare &       Medicaid Services;        (D) the Assistant Secretary for Mental Health and Substance       Use;        (E) the Assistant Secretary of Labor for Occupational       Safety and Health; and        (F) the Secretary of Veterans Affairs.        (c) Annual Reports.--Section 319C-2(i)(1) (42 U.S.C. 247d-      3b(i)(1)) is amended by inserting after the first sentence       the following: ``In submitting reports under this paragraph,       a coalition shall include information on the progress that       the coalition has made toward the implementation of section       319C-3 (or barriers to progress, if any).''.        (d) National Health Security Strategy Incorporation of       Regionalized Emergency Preparedness and Response.--      Subparagraph (G) of section 2802(b)(3) (42 U.S.C. 300hh-      1(b)(3)) is amended to read as follows:        ``(G) Optimizing a coordinated and flexible approach to the       emergency response and medical surge capacity of hospitals,       other health care facilities, critical care, trauma care       (which may include trauma centers), and emergency medical       systems.''.        (e) Improving State and Local Public Health Security.--  [[Page H10369]]         (1) State and local security.--Section 319C-1(e) (42 U.S.C.       247d-3a(e)) is amended by striking ``, and local emergency       plans.'' and inserting ``, local emergency plans, and any       regional health care emergency preparedness and response       system established pursuant to the applicable guidelines       under section 319C-3.''.        (2) Partnerships.--Section 319C-2(d)(1)(A) (42 U.S.C. 247d-      3b(d)(1)(A)) is amended--        (A) in clause (i), by striking ``; and'' and inserting       ``;'';        (B) by redesignating clause (ii) as clause (iii); and        (C) inserting after clause (i), the following:        ``(ii) among one or more facilities in a regional health       care emergency system under section 319C-3; and''.       SEC. 204. MILITARY AND CIVILIAN PARTNERSHIP FOR TRAUMA                     READINESS.         Title XII (42 U.S.C. 300d et seq.) is amended by adding at       the end the following new part:  ``PART I--MILITARY AND CIVILIAN PARTNERSHIP FOR TRAUMA READINESS GRANT                                  PROGRAM       ``SEC. 1291. MILITARY AND CIVILIAN PARTNERSHIP FOR TRAUMA                     READINESS GRANT PROGRAM.         ``(a) Military Trauma Team Placement Program.--        ``(1) In general.--The Secretary, acting through the       Assistant Secretary for Preparedness and Response and in       consultation with the Secretary of Defense, shall award       grants to not more than 20 eligible high acuity trauma       centers to enable military trauma teams to provide, on a       full-time basis, trauma care and related acute care at such       trauma centers.        ``(2) Limitations.--In the case of a grant awarded under       paragraph (1) to an eligible high acuity trauma center, such       grant--        ``(A) shall be for a period of at least 3 years and not       more than 5 years (and may be renewed at the end of such       period); and        ``(B) shall be in an amount that does not exceed $1,000,000       per year.        ``(3) Availability of funds.--Notwithstanding section 1552       of title 31, United States Code, or any other provision of       law, funds available to the Secretary for obligation for a       grant under this subsection shall remain available for       expenditure for 100 days after the last day of the       performance period of such grant.        ``(b) Military Trauma Care Provider Placement Program.--        ``(1) In general.--The Secretary, acting through the       Assistant Secretary for Preparedness and Response and in       consultation with the Secretary of Defense, shall award       grants to eligible trauma centers to enable military trauma       care providers to provide trauma care and related acute care       at such trauma centers.        ``(2) Limitations.--In the case of a grant awarded under       paragraph (1) to an eligible trauma center, such grant--        ``(A) shall be for a period of at least 1 year and not more       than 3 years (and may be renewed at the end of such period);       and        ``(B) shall be in an amount that does not exceed, in a       year--        ``(i) $100,000 for each military trauma care provider that       is a physician at such eligible trauma center; and        ``(ii) $50,000 for each other military trauma care provider       at such eligible trauma center.        ``(c) Grant Requirements.--        ``(1) Deployment and public health emergencies.--As a       condition of receipt of a grant under this section, a grant       recipient shall agree to allow military trauma care providers       providing care pursuant to such grant to--        ``(A) be deployed by the Secretary of Defense for military       operations, for training, or for response to a mass casualty       incident; and        ``(B) be deployed by the Secretary of Defense, in       consultation with the Secretary of Health and Human Services,       for response to a public health emergency pursuant to section       319.        ``(2) Use of funds.--Grants awarded under this section to       an eligible trauma center may be used to train and       incorporate military trauma care providers into such trauma       center, including incorporation into operational exercises       and training drills related to public health emergencies,       expenditures for malpractice insurance, office space,       information technology, specialty education and supervision,       trauma programs, research, and applicable license fees for       such military trauma care providers.        ``(d) Rule of Construction.--Nothing in this section shall       be construed to affect any other provision of law that       preempts State licensing requirements for health care       professionals, including with respect to military trauma care       providers.        ``(e) Reporting Requirements.--        ``(1) Report to the secretary and the secretary of       defense.--Each eligible trauma center or eligible high acuity       trauma center awarded a grant under subsection (a) or (b) for       a year shall submit to the Secretary and the Secretary of       Defense a report for such year that includes information on--        ``(A) the number and types of trauma cases managed by       military trauma teams or military trauma care providers       pursuant to such grant during such year;        ``(B) the ability to maintain the integration of the       military trauma providers or teams of providers as part of       the trauma center, including the financial effect of such       grant on the trauma center;        ``(C) the educational effect on resident trainees in       centers where military trauma teams are assigned;        ``(D) any research conducted during such year supported by       such grant; and        ``(E) any other information required by the Secretaries for       the purpose of evaluating the effect of such grant.        ``(2) Report to congress.--Not less than once every 2       years, the Secretary, in consultation with the Secretary of       Defense, shall submit a report to the congressional       committees of jurisdiction that includes information on the       effect of placing military trauma care providers in trauma       centers awarded grants under this section on--        ``(A) maintaining military trauma care providers' readiness       and ability to respond to and treat battlefield injuries;        ``(B) providing health care to civilian trauma patients in       urban and rural settings;        ``(C) the capability of trauma centers and military trauma       care providers to increase medical surge capacity, including       as a result of a large scale event;        ``(D) the ability of grant recipients to maintain the       integration of the military trauma providers or teams of       providers as part of the trauma center;        ``(E) efforts to incorporate military trauma care providers       into operational exercises and training and drills for public       health emergencies; and        ``(F) the capability of military trauma care providers to       participate as part of a medical response during or in       advance of a public health emergency, as determined by the       Secretary, or a mass casualty incident.        ``(f) Definitions.--For purposes of this part:        ``(1) Eligible trauma center.--The term `eligible trauma       center' means a Level I, II, or III trauma center that       satisfies each of the following:        ``(A) Such trauma center has an agreement with the       Secretary of Defense to enable military trauma care providers       to provide trauma care and related acute care at such trauma       center.        ``(B) Such trauma center utilizes a risk-adjusted       benchmarking system and metrics to measure performance,       quality, and patient outcomes.        ``(C) Such trauma center demonstrates a need for integrated       military trauma care providers to maintain or improve the       trauma clinical capability of such trauma center.        ``(2) Eligible high acuity trauma center.--The term       `eligible high acuity trauma center' means a Level I trauma       center that satisfies each of the following:        ``(A) Such trauma center has an agreement with the       Secretary of Defense to enable military trauma teams to       provide trauma care and related acute care at such trauma       center.        ``(B) At least 20 percent of patients treated at such       trauma center in the most recent 3-month period for which       data are available are treated for a major trauma at such       trauma center.        ``(C) Such trauma center utilizes a risk-adjusted       benchmarking system and metrics to measure performance,       quality, and patient outcomes.        ``(D) Such trauma center is an academic training center--        ``(i) affiliated with a medical school;        ``(ii) that maintains residency programs and fellowships in       critical trauma specialties and subspecialties, and provides       education and supervision of military trauma team members       according to those specialties and subspecialties; and        ``(iii) that undertakes research in the prevention and       treatment of traumatic injury.        ``(E) Such trauma center serves as a medical and public       health preparedness and response leader for its community,       such as by participating in a partnership for State and       regional hospital preparedness established under section       319C-2 or 319C-3.        ``(3) Major trauma.--The term `major trauma' means an       injury that is greater than or equal to 15 on the injury       severity score.        ``(4) Military trauma team.--The term `military trauma       team' means a complete military trauma team consisting of       military trauma care providers.        ``(5) Military trauma care provider.--The term `military       trauma care provider' means a member of the Armed Forces who       furnishes emergency, critical care, and other trauma acute       care services (including a physician, surgeon, physician       assistant, nurse, nurse practitioner, respiratory therapist,       flight paramedic, combat medic, or enlisted medical       technician) or other military trauma care provider as the       Secretary determines appropriate.        ``(g) Authorization of Appropriations.--To carry out this       section, there are authorized to be appropriated $11,500,000       for each of fiscal years 2019 through 2023.''.       SEC. 205. PUBLIC HEALTH AND HEALTH CARE SYSTEM SITUATIONAL                     AWARENESS AND BIOSURVEILLANCE CAPABILITIES.         (a) Facilities, Capacities, and Biosurveillance       Capabilities.--Section 319D (42 U.S.C. 247d-4) is amended--        (1) in the section heading, by striking ``revitalizing''       and inserting ``facilities and capacities of'';        (2) in subsection (a)--        (A) in the subsection heading, by striking ``Facilities;       Capacities'' and inserting ``In General'';        (B) in paragraph (1), by striking ``and improved'' and       inserting ``, improved, and appropriately maintained'';        (C) in paragraph (3), in the matter preceding subparagraph       (A), by striking ``expand, enhance, and improve'' and       inserting  [[Page H10370]]       ``expand, improve, enhance, and appropriately maintain''; and        (D) by adding at the end the following:        ``(4) Study of resources for facilities and capacities.--      Not later than June 1, 2022, the Comptroller General of the       United States shall conduct a study on Federal spending in       fiscal years 2013 through 2018 for activities authorized       under this subsection. Such study shall include a review and       assessment of obligations and expenditures directly related       to each activity under paragraphs (2) and (3), including a       specific accounting of, and delineation between, obligations       and expenditures incurred for the construction, renovation,       equipping, and security upgrades of facilities and associated       contracts under this subsection, and the obligations and       expenditures incurred to establish and improve the       situational awareness and biosurveillance network under       subsection (b), and shall identify the agency or agencies       incurring such obligations and expenditures.'';        (3) in subsection (b)--        (A) in the subsection heading, by striking ``National'' and       inserting ``Establishment of Systems of Public Health'';        (B) in paragraph (1)(B), by inserting ``immunization       information systems,'' after ``centers,''; and        (C) in paragraph (2)--        (i) by inserting ``develop a plan to, and'' after ``The       Secretary shall''; and        (ii) by inserting ``and in a form readily usable for       analytical approaches'' after ``in a secure manner''; and        (D) by amending paragraph (3) to read as follows:        ``(3) Standards.--        ``(A) In general.--Not later than 1 year after the date of       the enactment of the Pandemic and All-Hazards Preparedness       and Advancing Innovation Act of 2018, the Secretary, in       cooperation with health care providers, State, local, tribal,       and territorial public health officials, and relevant Federal       agencies (including the Office of the National Coordinator       for Health Information Technology and the National Institute       of Standards and Technology), shall, as necessary, adopt       technical and reporting standards, including standards for       interoperability as defined by section 3000, for networks       under paragraph (1) and update such standards as necessary.       Such standards shall be made available on the internet       website of the Department of Health and Human Services, in a       manner that does not compromise national security.        ``(B) Deference to standards development organizations.--In       adopting and implementing standards under this subsection and       subsection (c), the Secretary shall give deference to       standards published by standards development organizations       and voluntary consensus-based standards entities.'';        (4) in subsection (c)--        (A) in paragraph (1)--        (i) by striking ``Not later than 2 years after the date of       enactment of the Pandemic and All-Hazards Preparedness       Reauthorization Act of 2013, the Secretary'' and inserting       ``The Secretary'';        (ii) by inserting ``, and improve as applicable and       appropriate,'' after ``shall establish'';        (iii) by striking ``of rapid'' and inserting ``of, rapid'';       and        (iv) by striking ``such connectivity'' and inserting ``such       interoperability'';        (B) by amending paragraph (2) to read as follows:        ``(2) Coordination and consultation.--In establishing and       improving the network under paragraph (1) the Secretary       shall--        ``(A) facilitate coordination among agencies within the       Department of Health and Human Services that provide, or have       the potential to provide, information and data to, and       analyses for, the situational awareness and biosurveillance       network under paragraph (1), including coordination among       relevant agencies related to health care services, the       facilitation of health information exchange (including the       Office of the National Coordinator for Health Information       Technology), and public health emergency preparedness and       response; and        ``(B) consult with the Secretary of Agriculture, the       Secretary of Commerce (and the Director of the National       Institute of Standards and Technology), the Secretary of       Defense, the Secretary of Homeland Security, the Secretary of       Veterans Affairs, and the heads of other Federal agencies, as       the Secretary determines appropriate.'';        (C) in paragraph (3)--        (i) by redesignating subparagraphs (A) through (E) as       clauses (i) through (v), respectively, and adjusting the       margins accordingly;        (ii) in clause (iv), as so redesignated--         (I) by inserting ``immunization information systems,''       after ``poison control,''; and        (II) by striking ``and clinical laboratories'' and       inserting ``, clinical laboratories, and public environmental       health agencies'';         (iii) by striking ``The network'' and inserting the       following:        ``(A) In general.--The network''; and        (iv) by adding at the end the following:        ``(B) Review.--Not later than 2 years after the date of the       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018 and every 6 years       thereafter, the Secretary shall conduct a review of the       elements described in subparagraph (A). Such review shall       include a discussion of the addition of any elements pursuant       to clause (v), including elements added to advancing new       technologies, and identify any challenges in the       incorporation of elements under subparagraph (A). The       Secretary shall provide such review to the congressional       committees of jurisdiction.'';        (D) in paragraph (5)--        (i) by redesignating subparagraphs (A) through (D) as       clauses (i) through (iv), respectively, and adjusting the       margins accordingly;        (ii) by striking ``In establishing'' and inserting the       following:        ``(A) In general.--In establishing'';        (iii) by adding at the end the following:        ``(B) Public meeting.--        ``(i) In general.--Not later than 180 days after the date       of enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, the Secretary shall convene       a public meeting for purposes of discussing and providing       input on the potential goals, functions, and uses of the       network described in paragraph (1) and incorporating the       elements described in paragraph (3)(A).        ``(ii) Experts.--The public meeting shall include       representatives of relevant Federal agencies (including       representatives from the Office of the National Coordinator       for Health Information Technology and the National Institute       of Standards and Technology); State, local, tribal, and       territorial public health officials; stakeholders with       expertise in biosurveillance and situational awareness;       stakeholders with expertise in capabilities relevant to       biosurveillance and situational awareness, such as experts in       informatics and data analytics (including experts in       prediction, modeling, or forecasting); and other       representatives as the Secretary determines appropriate.        ``(iii) Topics.--Such public meeting shall include a       discussion of--         ``(I) data elements, including minimal or essential data       elements, that are voluntarily provided for such network,       which may include elements from public health and public and       private health care entities, to the extent practicable;        ``(II) standards and implementation specifications that may       improve the collection, analysis, and interpretation of data       during a public health emergency;        ``(III) strategies to encourage the access, exchange, and       use of information;        ``(IV) considerations for State, local, tribal, and       territorial capabilities and infrastructure related to data       exchange and interoperability;        ``(V) privacy and security protections provided at the       Federal, State, local, tribal, and territorial levels, and by       nongovernmental stakeholders; and        ``(VI) opportunities for the incorporation of innovative       technologies to improve the network.''; and         (iv) in subparagraph (A), as so designated by clause (ii)--         (I) in clause (i), as so redesignated--         (aa) by striking ``as determined'' and inserting ``as       adopted''; and        (bb) by inserting ``and the National Institute of Standards       and Technology'' after ``Office of the National Coordinator       for Health Information Technology'';         (II) in clause (iii), as so redesignated, by striking ``;       and'' and inserting a semicolon;        (III) in clause (iv), as so redesignated, by striking the       period and inserting ``; and''; and        (IV) by adding at the end the following:         ``(v) pilot test standards and implementation       specifications, consistent with the process described in       section 3002(b)(3)(C), which State, local, tribal, and       territorial public health entities may utilize, on a       voluntary basis, as a part of the network.'';        (E) by redesignating paragraph (6) as paragraph (7);        (F) by inserting after paragraph (5) the following:        ``(6) Strategy and implementation plan.--        ``(A) In general.--Not later than 18 months after the date       of enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, the Secretary shall submit       to the congressional committees of jurisdiction a coordinated       strategy and an accompanying implementation plan that--        ``(i) is informed by the public meeting under paragraph       (5)(B);        ``(ii) includes a review and assessment of existing       capabilities of the network and related infrastructure,       including input provided by the public meeting under       paragraph (5)(B);        ``(iii) identifies and demonstrates the measurable steps       the Secretary will carry out to--         ``(I) develop, implement, and evaluate the network       described in paragraph (1), utilizing elements described in       paragraph (3)(A);        ``(II) modernize and enhance biosurveillance activities,       including strategies to include innovative technologies and       analytical approaches (including prediction and forecasting       for pandemics and all-hazards) from public and private       entities;        ``(III) improve information sharing, coordination, and       communication among disparate biosurveillance systems       supported by the Department of Health and Human Services,       including the identification of methods to improve       accountability, better utilize resources and workforce       capabilities, and incorporate innovative technologies within       and across agencies; and        ``(IV) test and evaluate capabilities of the interoperable       network of systems to improve situational awareness and       biosurveillance capabilities;         ``(iv) includes performance measures and the metrics by       which performance measures  [[Page H10371]]       will be assessed with respect to the measurable steps under       clause (iii); and        ``(v) establishes dates by which each measurable step under       clause (iii) will be implemented.        ``(B) Annual budget plan.--Not later than 2 years after the       date of enactment of the Pandemic and All-Hazards       Preparedness and Advancing Innovation Act of 2018 and on an       annual basis thereafter, in accordance with the strategy and       implementation plan under this paragraph, the Secretary       shall, taking into account recommendations provided by the       National Biodefense Science Board, develop a budget plan       based on the strategy and implementation plan under this       section. Such budget plan shall include--        ``(i) a summary of resources previously expended to       establish, improve, and utilize the nationwide public health       situational awareness and biosurveillance network under       paragraph (1);        ``(ii) estimates of costs and resources needed to establish       and improve the network under paragraph (1) according to the       strategy and implementation plan under subparagraph (A);        ``(iii) the identification of gaps and inefficiencies in       nationwide public health situational awareness and       biosurveillance capabilities, resources, and authorities       needed to address such gaps; and        ``(iv) a strategy to minimize and address such gaps and       improve inefficiencies.'';        (G) in paragraph (7), as so redesignated--        (i) in subparagraph (A), by inserting ``(taking into       account zoonotic disease, including gaps in scientific       understanding of the interactions between human, animal, and       environmental health)'' after ``human health'';        (ii) in subparagraph (B)--         (I) by inserting ``and gaps in surveillance programs''       after ``surveillance programs''; and        (II) by striking ``; and'' and inserting a semicolon;         (iii) in subparagraph (C)--         (I) by inserting ``, animal health organizations related to       zoonotic disease,'' after ``health care entities''; and        (II) by striking the period and inserting ``; and''; and         (iv) by adding at the end the following:        ``(D) provide recommendations to the Secretary on policies       and procedures to complete the steps described in this       paragraph in a manner that is consistent with section       2802.''; and        (H) by adding at the end the following:        ``(8) Situational awareness and biosurveillance as a       national security priority.--The Secretary, on a periodic       basis as applicable and appropriate, shall meet with the       Director of National Intelligence to inform the development       and capabilities of the nationwide public health situational       awareness and biosurveillance network.'';        (5) in subsection (d)--        (A) in paragraph (1)--        (i) by inserting ``environmental health agencies,'' after       ``public health agencies,''; and        (ii) by inserting ``immunization programs,'' after ``poison       control centers,''; and        (B) in paragraph (2)--        (i) in subparagraph (B), by striking ``and'' at the end;        (ii) in subparagraph (C), by striking the period and       inserting ``; and''; and        (iii) by adding after subparagraph (C) the following:        ``(D) an implementation plan that may include measurable       steps to achieve the purposes described in paragraph (1).'';       and        (C) by striking paragraph (5) and inserting the following:        ``(5) Technical assistance.--The Secretary may provide       technical assistance to States, localities, tribes, and       territories or a consortium of States, localities, tribes,       and territories receiving an award under this subsection       regarding interoperability and the technical standards set       forth by the Secretary.'';        (6) by redesignating subsections (f) and (g) as subsections       (i) and (j), respectively; and        (7) by inserting after subsection (e) the following:        ``(f) Personnel Authorities.--        ``(1) Specially qualified personnel.--In addition to any       other personnel authorities, to carry out subsections (b) and       (c), the Secretary may--        ``(A) appoint highly qualified individuals to scientific or       professional positions at the Centers for Disease Control and       Prevention, not to exceed 30 such employees at any time       (specific to positions authorized by this subsection), with       expertise in capabilities relevant to biosurveillance and       situational awareness, such as experts in informatics and       data analytics (including experts in prediction, modeling, or       forecasting), and other related scientific or technical       fields; and        ``(B) compensate individuals appointed under subparagraph       (A) in the same manner and subject to the same terms and       conditions in which individuals appointed under 9903 of title       5, United States Code, are compensated, without regard to the       provisions of chapter 51 and subchapter III of chapter 53 of       such title relating to classification and General Schedule       pay rates.        ``(2) Limitations.--The Secretary shall exercise the       authority under paragraph (1) in a manner that is consistent       with the limitations described in section 319F-1(e)(2).        ``(g) Timeline.--The Secretary shall accomplish the       purposes under subsections (b) and (c) no later than       September 30, 2023, and shall provide a justification to the       congressional committees of jurisdiction for any missed or       delayed implementation of measurable steps identified under       subsection (c)(6)(A)(iii).        ``(h) Independent Evaluation.--Not later than 3 years after       the date of enactment of the Pandemic and All-Hazards       Preparedness and Advancing Innovation Act of 2018, the       Comptroller General of the United States shall conduct an       independent evaluation and submit to the Secretary and the       congressional committees of jurisdiction a report concerning       the activities conducted under subsections (b) and (c), and       provide recommendations, as applicable and appropriate, on       necessary improvements to the biosurveillance and situational       awareness network.''.        (b) Authorization of Appropriations.--Subsection (i) of       section 319D (42 U.S.C. 247d-4), as redesignated by       subsection (a)(6), is amended by striking ``$138,300,000 for       each of fiscal years 2014 through 2018'' and inserting       ``$161,800,000 for each of fiscal years 2019 through 2023''.        (c) Biological Threat Detection Report.--The Secretary of       Health and Human Services shall, in coordination with the       Secretary of Defense and the Secretary of Homeland Security,       not later than 180 days after the date of enactment of this       Act, report to the Committee on Energy and Commerce, the       Committee on Armed Services, and the Committee on Homeland       Security of the House of Representatives and the Committee on       Health, Education, Labor, and Pensions, the Committee on       Armed Services, and the Committee on Homeland Security and       Governmental Affairs of the Senate on the state of Federal       biological threat detection efforts, including the       following--        (1) an identification of technological, operational, and       programmatic successes and failures of domestic detection       programs supported by Federal departments and agencies for       intentionally-introduced or accidentally-released biological       threat agents and naturally occurring infectious diseases;        (2) a description of Federal efforts to facilitate the       exchange of information related to the information described       in paragraph (1) among Federal departments and agencies that       utilize biological threat detection technology;        (3) a description of the capabilities of detection systems       in use by Federal departments and agencies including the       capability to--        (A) rapidly detect, identify, characterize, and confirm the       presence of biological threat agents;        (B) recover live biological agents from collection devices;        (C) determine the geographical distribution of biological       agents;        (D) determine the extent of environmental contamination and       persistence of biological agents; and        (E) provide advanced molecular diagnostics to State, local,       tribal, and territorial public health and other laboratories       that support biological threat detection activities;        (4) a description of Federal interagency coordination       related to biological threat detection;        (5) a description of efforts by Federal departments and       agencies that utilize biological threat detection technology       to collaborate with State, local, tribal, and territorial       public health laboratories and other users of biological       threat detection systems, including collaboration regarding       the development of--        (A) biological threat detection requirements or standards;        (B) a standardized integration strategy;        (C) training requirements or guidelines;        (D) guidelines for a coordinated public health response,       including preparedness capabilities, and, as applicable, for       coordination with public health surveillance systems; and        (E) a coordinated environmental remediation plan, as       applicable; and        (6) recommendations related to research, advanced research,       development, and procurement for Federal departments and       agencies to improve and enhance biological threat detection       systems, including recommendations on the transfer of       biological threat detection technology among Federal       departments and agencies, as necessary and appropriate.       SEC. 206. STRENGTHENING AND SUPPORTING THE PUBLIC HEALTH                     EMERGENCY RAPID RESPONSE FUND.         Section 319 (42 U.S.C. 247d) is amended--        (1) in subsection (b)--        (A) in paragraph (1)--        (i) in the first sentence, by inserting ``or if the       Secretary determines there is the significant potential for a       public health emergency, to allow the Secretary to rapidly       respond to the immediate needs resulting from such public       health emergency or potential public health emergency''       before the period; and        (ii) by inserting ``The Secretary shall plan for the       expedited distribution of funds to appropriate agencies and       entities.'' after the first sentence;        (B) by redesignating paragraph (2) as paragraph (3);        (C) by inserting after paragraph (1) the following:        ``(2) Uses.--The Secretary may use amounts in the Fund       established under paragraph (1), to--        ``(A) facilitate coordination between and among Federal,       State, local, tribal, and territorial entities and public and       private health care entities that the Secretary determines       may be affected by a public health  [[Page H10372]]       emergency or potential public health emergency referred to in       paragraph (1) (including communication of such entities with       relevant international entities, as applicable);        ``(B) make grants, provide for awards, enter into       contracts, and conduct supportive investigations pertaining       to a public health emergency or potential public health       emergency, including further supporting programs under       section 319C-1, 319C-2, or 319C-3;        ``(C) facilitate and accelerate, as applicable, advanced       research and development of security countermeasures (as       defined in section 319F-2), qualified countermeasures (as       defined in section 319F-1), or qualified pandemic or epidemic       products (as defined in section 319F-3), that are applicable       to the public health emergency or potential public health       emergency under paragraph (1);        ``(D) strengthen biosurveillance capabilities and       laboratory capacity to identify, collect, and analyze       information regarding such public health emergency or       potential public health emergency, including the systems       under section 319D;        ``(E) support initial emergency operations and assets       related to preparation and deployment of intermittent       disaster response personnel under section 2812 and the       Medical Reserve Corps under section 2813; and        ``(F) carry out other activities, as the Secretary       determines applicable and appropriate.''; and        (D) by inserting after paragraph (3), as so redesignated,       the following:        ``(4) Review.--Not later than 2 years after the date of       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, the Secretary, in       coordination with the Assistant Secretary for Preparedness       and Response, shall conduct a review of the Fund under this       section and provide recommendations to the Committee on       Health, Education, Labor, and Pensions and the Committee on       Appropriations of the Senate and the Committee on Energy and       Commerce and the Committee on Appropriations of the House of       Representatives on policies to improve such Fund for the uses       described in paragraph (2).        ``(5) GAO report.--Not later than 4 years after the date of       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, the Comptroller General of       the United States shall--        ``(A) conduct a review of the Fund under this section,       including its uses and the resources available in the Fund;       and        ``(B) submit to the Committee on Health, Education, Labor,       and Pensions of the Senate and the Committee on Energy and       Commerce of the House of Representatives a report on such       review, including recommendations related to such review, as       applicable.''; and        (2) in subsection (c)--        (A) by inserting ``rapidly respond to public health       emergencies or potential public health emergencies and''       after ``used to''; and        (B) by striking ``section.'' and inserting ``Act or funds       otherwise provided for emergency response.''.       SEC. 207. IMPROVING ALL-HAZARDS PREPAREDNESS AND RESPONSE BY                     PUBLIC HEALTH EMERGENCY VOLUNTEERS.         (a) In General.--Section 319I (42 U.S.C. 247d-7b) is       amended--        (1) in the section heading, by striking ``health       professions volunteers'' and inserting ``volunteer health       professional'';        (2) in subsection (a), by adding at the end the following:       ``Such health care professionals may include members of the       National Disaster Medical System, members of the Medical       Reserve Corps, and individual health care professionals.'';        (3) in subsection (i) by adding at the end ``In order to       inform the development of such mechanisms by States, the       Secretary shall make available information and material       provided by States that have developed mechanisms to waive       the application of licensing requirements to applicable       health professionals seeking to provide medical services       during a public health emergency. Such information shall be       made publicly available in a manner that does not compromise       national security.''; and        (4) in subsection (k) by striking ``2014 through 2018'' and       inserting ``2019 through 2023''.        (b) All-Hazards Public Health Emergency Preparedness and       Response Plan.--Section 319C-1(b)(2)(A)(iv) (42 U.S.C. 247d-      3a(b)(2)(A)(iv)) is amended to read as follows:        ``(iv) a description of the mechanism the entity will       implement to utilize the Emergency Management Assistance       Compact, or other mutual aid agreement, for medical and       public health mutual aid, and, as appropriate, the activities       such entity will implement pursuant to section 319I to       improve enrollment and coordination of volunteer health care       professionals seeking to provide medical services during a       public health emergency, which may include--        ``(I) providing a public method of communication for       purposes of volunteer coordination (such as a phone number);        ``(II) providing for optional registration to participate       in volunteer services during processes related to State       medical licensing, registration, or certification or renewal       of such licensing, registration or certification; or        ``(III) other mechanisms as the State determines       appropriate;''.       SEC. 208. CLARIFYING STATE LIABILITY LAW FOR VOLUNTEER HEALTH                     CARE PROFESSIONALS.         (a) In General.--Title II (42 U.S.C. 202 et seq.) is       amended by inserting after section 224 the following:       ``SEC. 225. HEALTH CARE PROFESSIONALS ASSISTING DURING A                     PUBLIC HEALTH EMERGENCY.         ``(a) Limitation on Liability.--Notwithstanding any other       provision of law, a health care professional who is a member       of the Medical Reserve Corps under section 2813 or who is       included in the Emergency System for Advance Registration of       Volunteer Health Professionals under section 319I and who--        ``(1) is responding--        ``(A) to a public health emergency determined under section       319(a), during the initial period of not more than 90 days       (as determined by the Secretary) of the public health       emergency determination (excluding any period covered by a       renewal of such determination); or        ``(B) to a major disaster or an emergency as declared by       the President under section 401 of the Robert T. Stafford       Disaster Relief and Emergency Assistance Act (42 U.S.C. 5170)       or under section 201 of the National Emergencies Act (50       U.S.C.1621) during the initial period of such declaration;       and        ``(2) is alleged to be liable for an act or omission--        ``(A) during the initial period of a determination or       declaration described in paragraph (1) and related to the       treatment of individuals in need of health care services due       to such public health emergency, major disaster, or       emergency;        ``(B) in the State or States for which such determination       or declaration is made;        ``(C) in the health care professional's capacity as a       member of the Medical Reserve Corps or a professional       included in the Emergency System for Advance Registration of       Volunteer Health Professionals under section 319I; and        ``(D) in the course of providing services that are within       the scope of the license, registration, or certification of       the professional, as defined by the State of licensure,       registration, or certification; and        ``(3) prior to the rendering of such act or omission, was       authorized by the State's authorization of deploying such       State's Emergency System for Advance Registration of       Volunteer Health Professionals described in section 319I or       the Medical Reserve Corps established under section 2813, to       provide health care services,       shall be subject only to the State liability laws of the       State in which such act or omission occurred, in the same       manner and to the same extent as a similar health care       professional who is a resident of such State would be subject       to such State laws, except with respect to the licensure,       registration, and certification of such individual.        ``(b) Volunteer Protection Act.--Nothing in this section       shall be construed to affect an individual's right to       protections under the Volunteer Protection Act of 1997.        ``(c) Preemption.--This section shall supersede the laws of       any State that would subject a health care professional       described in subsection (a) to the liability laws of any       State other than the State liability laws to which such       individual is subject pursuant to such subsection.        ``(d) Definitions.--In this section:        ``(1) The term `health care professional' means an       individual licensed, registered, or certified under Federal       or State laws or regulations to provide health care services.        ``(2) The term `health care services' means any services       provided by a health care professional, or by any individual       working under the supervision of a health care professional,       that relate to--        ``(A) the diagnosis, prevention, or treatment of any human       disease or impairment; or        ``(B) the assessment or care of the health of human beings.        ``(e) Effective Date.--        ``(1) In general.--This section shall take effect 90 days       after the date of the enactment of the Pandemic and All-      Hazards Preparedness and Advancing Innovation Act of 2018.        ``(2) Application.--This section shall apply to a claim for       harm only if the act or omission that caused such harm       occurred on or after the effective date described in       paragraph (1).''.        (b) GAO Study.--Not later than one year after the date of       enactment of this Act, the Comptroller General of the United       States shall conduct a review of--        (1) the number of health care providers who register under       the Emergency System for Advance Registration of Volunteer       Health Professionals under section 319I of the Public Health       Service Act (42 U.S.C. 247d-7b) in advance to provide       services during a public health emergency;        (2) the number of health care providers who are       credentialed to provide services during the period of a       public health emergency declaration, including those who are       credentialed though programs established in the Emergency       System for Advance Registration of Volunteer Health       Professionals under such section 319I and those credentialed       by authorities within the State in which the emergency       occurred;        (3) the average time to verify the credentials of a health       care provider during the period of a public health emergency       declaration, including the average time pursuant to the       Emergency System for Advance Registration of Volunteer Health       Professionals under such section 319I and for an individual's       credentials to be verified by an authority within the State;       and  [[Page H10373]]         (4) the Emergency System for Advance Registration of       Volunteer Health Professionals program in States, including       whether physician or medical groups, associations, or other       relevant provider organizations utilize such program for       purposes of volunteering during public health emergencies.       SEC. 209. REPORT ON ADEQUATE NATIONAL BLOOD SUPPLY.         Not later than 1 year after the date of the enactment of       this Act, the Secretary of Health and Human Services shall       submit to Congress a report containing recommendations       related to maintaining an adequate national blood supply,       including--        (1) challenges associated with the continuous recruitment       of blood donors (including those newly eligible to donate);        (2) ensuring the adequacy of the blood supply in the case       of public health emergencies;        (3) implementation of the transfusion transmission       monitoring system; and        (4) other measures to promote safety and innovation, such       as the development, use, or implementation of new       technologies, processes, and procedures to improve the safety       and reliability of the blood supply.       SEC. 210. REPORT ON THE PUBLIC HEALTH PREPAREDNESS AND                     RESPONSE CAPABILITIES AND CAPACITIES OF                     HOSPITALS, LONG-TERM CARE FACILITIES, AND OTHER                     HEALTH CARE FACILITIES.         (a) Study.--        (1) In general.--Not later than one year after the date of       enactment of this Act, the Secretary of Health and Human       Services shall enter into an agreement with an appropriate       entity to conduct a study regarding the public health       preparedness and response capabilities and medical surge       capacities of hospitals, long-term care facilities, and other       health care facilities to prepare for, and respond to, public       health emergencies, including natural disasters.        (2) Consultation.--In conducting the study under paragraph       (1), the entity shall consult with Federal, State, local,       tribal, and territorial public health officials (as       appropriate), and health care providers and facilities with       experience in public health preparedness and response       activities.        (3) Evaluation.--The study under paragraph (1) shall       include--        (A) an evaluation of the current benchmarks and objective       standards, as applicable, related to programs that support       hospitals, long-term care facilities, and other health care       facilities, and their effect on improving public health       preparedness and response capabilities and medical surge       capacities, including the Hospital Preparedness Program, the       Public Health Emergency Preparedness cooperative agreements,       and the Regional Health Care Emergency Preparedness and       Response Systems under section 319C-3 of the Public Health       Service Act (as added by section 203);        (B) the identification of gaps in preparedness, including       with respect to such benchmarks and objective standards, such       as those identified during recent public health emergencies,       for hospitals, long-term care facilities, and other health       care facilities to address future potential public health       threats;        (C) an evaluation of coordination efforts between the       recipients of Federal funding for programs described in       subparagraph (A) and entities with expertise in emergency       power systems and other critical infrastructure partners       during a public health emergency, to ensure a functioning       critical infrastructure, to the greatest extent practicable,       during a public health emergency;        (D) an evaluation of coordination efforts between the       recipients of Federal funding for programs described in       subparagraph (A) and environmental health agencies with       expertise in emergency preparedness and response planning for       hospitals, long-term care facilities, and other health care       facilities; and        (E) an evaluation of current public health preparedness and       response capabilities and medical surge capacities related to       at-risk individuals during public health emergencies,       including an identification of gaps in such preparedness as       they relate to such individuals.        (b) Report.--        (1) In general.--The agreement under subsection (a) shall       require the entity to submit to the Secretary of Health and       Human Services and the congressional committees of       jurisdiction, not later than 3 years after the date of       enactment of this Act, a report on the results of the study       conducted pursuant to this section.        (2) Contents.--The report under paragraph (1) shall--        (A) describe the findings and conclusions of the evaluation       conducted pursuant to subsection (a); and        (B) provide recommendations for improving public health       preparedness and response capability and medical surge       capacity for hospitals, long-term care facilities, and other       health care facilities, including--        (i) improving the existing benchmarks and objective       standards for the Federal grant programs described in       subsection (a)(3)(A) or developing new benchmarks and       standards for such programs; and        (ii) identifying best practices for improving public health       preparedness and response programs and medical surge capacity       at hospitals, long-term care facilities, and other health       care facilities, including recommendations for the evaluation       under subparagraphs (C) and (D) of subsection (a)(3).                    TITLE III--REACHING ALL COMMUNITIES       SEC. 301. STRENGTHENING AND ASSESSING THE EMERGENCY RESPONSE                     WORKFORCE.         (a) National Disaster Medical System.--        (1) Strengthening the national disaster medical system.--      Clause (ii) of section 2812(a)(3)(A) (42 U.S.C. 300hh-      11(a)(3)(A)) is amended to read as follows:        ``(ii) be present at locations, and for limited periods of       time, specified by the Secretary on the basis that the       Secretary has determined that a location is at risk of a       public health emergency during the time specified, or there       is a significant potential for a public health emergency.''.        (2) Review of the national disaster medical system.--      Section 2812(b)(2) (42 U.S.C. 300hh-11(b)(2)) is amended to       read as follows:        ``(2) Joint review and medical surge capacity strategic       plan.--        ``(A) Review.--Not later than 180 days after the date of       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, the Secretary, in       coordination with the Secretary of Homeland Security, the       Secretary of Defense, and the Secretary of Veterans Affairs,       shall conduct a joint review of the National Disaster Medical       System. Such review shall include--        ``(i) an evaluation of medical surge capacity, as described       in section 2803(a);        ``(ii) an assessment of the available workforce of the       intermittent disaster response personnel described in       subsection (c);        ``(iii) the capacity of the workforce described in clause       (ii) to respond to all hazards, including capacity to       simultaneously respond to multiple public health emergencies       and the capacity to respond to a nationwide public health       emergency;        ``(iv) the effectiveness of efforts to recruit, retain, and       train such workforce; and        ``(v) gaps that may exist in such workforce and       recommendations for addressing such gaps.        ``(B) Updates.--As part of the National Health Security       Strategy under section 2802, the Secretary shall update the       findings from the review under subparagraph (A) and provide       recommendations to modify the policies of the National       Disaster Medical System as necessary.''.        (3) Notification of shortage.--Section 2812(c) (42 U.S.C.       300hh-11(c)) is amended by adding at the end the following:        ``(3) Notification.--Not later than 30 days after the date       on which the Secretary determines the number of intermittent       disaster-response personnel of the National Disaster Medical       System is insufficient to address a public health emergency       or potential public health emergency, the Secretary shall       submit to the congressional committees of jurisdiction a       notification detailing--        ``(A) the impact such shortage could have on meeting public       health needs and emergency medical personnel needs during a       public health emergency; and        ``(B) any identified measures to address such shortage.        ``(4) Certain appointments.--        ``(A) In general.--If the Secretary determines that the       number of intermittent disaster response personnel within the       National Disaster Medical System under this section is       insufficient to address a public health emergency or       potential public health emergency, the Secretary may appoint       candidates directly to personnel positions for intermittent       disaster response within such system. The Secretary shall       provide updates on the number of vacant or unfilled positions       within such system to the congressional committees of       jurisdiction each quarter for which this authority is in       effect.        ``(B) Sunset.--The authority under this paragraph shall       expire on September 30, 2021.''.        (4) Authorization of appropriations.--Section 2812(g) (42       U.S.C. 300hh-11(g)) is amended by striking ``$52,700,000 for       each of fiscal years 2014 through 2018'' and inserting       ``$57,400,000 for each of fiscal years 2019 through 2023''.        (b) Volunteer Medical Reserve Corps.--        (1) In general.--Section 2813(a) (42 U.S.C. 42 U.S.C.       300hh-15(a)) is amended by striking the second sentence and       inserting ``The Secretary may appoint a Director to head the       Corps and oversee the activities of the Corps chapters that       exist at the State, local, tribal, and territorial levels.''.        (2) Authorization of appropriations.--Section 2813(i) (42       U.S.C. 300hh-15(i)) is amended by striking ``2014 through       2018'' and inserting ``2019 through 2023''.        (c) Strengthening the Epidemic Intelligence Service.--      Section 317F (42 U.S.C. Sec. 247b-7) is amended--        (1) in subsection (a)--        (A) in paragraph (1)--        (i) by inserting ``or preparedness and response activities,       including rapid response to public health emergencies and       significant public health threats'' after ``conduct       prevention activities''; and        (ii) by striking ``$35,000'' and inserting ``$50,000''; and        (B) in paragraph (2)(B), by striking ``3 years'' and       inserting ``2 years''; and        (2) in subsection (c)--        (A) by striking ``For the purpose of carrying out this       section'' and inserting the following:        ``(1) In general.--For the purpose of carrying out this       section, except as described in paragraph (2)''; and        (B) by adding at the end the following:        ``(2) Epidemic intelligence service program.--For purposes       of carrying out this section with respect to qualified health       professionals serving in the Epidemic Intelligence Service,       as authorized under section 317G,  [[Page H10374]]       there are authorized to be appropriated $1,000,000 for each       of fiscal years 2019 through 2023.''.        (d) Service Benefit for National Disaster Medical System       Volunteers.--        (1) In general.--Section 2812(c) (42 U.S.C. 300hh-11(c)),       as amended by subsection (a)(3), is further amended by adding       at the end the following:        ``(5) Service benefit.--Individuals appointed to serve       under this subsection shall be considered eligible for       benefits under part L of title I of the Omnibus Crime Control       and Safe Streets Act of 1968. The Secretary shall provide       notification to any eligible individual of any effect such       designation may have on other benefits for which such       individual is eligible, including benefits from private       entities.''.        (2) Public safety officer benefits.--Section 1204(9) of       title I of the Omnibus Crime Control and Safe Streets Act of       1968 (34 U.S.C. 10284(9)) is amended--        (A) in subparagraph (C)(ii), by striking ``or'' at the end;        (B) in subparagraph (D), by striking the period and       inserting ``; or''; and        (C) by inserting after subparagraph (D) the following:        ``(E) an individual appointed to the National Disaster       Medical System under section 2812 of the Public Health       Service Act (42 U.S.C. 300hh-11) who is performing official       duties of the Department of Health and Human Services, if       those official duties are--        ``(i) related to responding to a public health emergency or       potential public health emergency, or other activities for       which the Secretary of Health and Human Services has       activated such National Disaster Medical System; and        ``(ii) determined by the Secretary of Health and Human       Services to be hazardous.''.        (3) Sunset.--The amendments made by paragraphs (1) and (2)       shall cease to have force or effect on October 1, 2021.        (e) Mission Readiness Report to Congress.--        (1) Report.--Not later than one year after the date of       enactment of this section, the Comptroller General of the       United States (referred to in this subsection as the       ``Comptroller General'') shall submit to the Committee on       Health, Education, Labor, and Pensions of the Senate and the       Committee on Energy and Commerce of the House of       Representatives, a report on the medical surge capacity of       the United States in the event of a public health emergency,       including the capacity and capability of the current health       care workforce to prepare for, and respond to the full range       of public health emergencies or potential public health       emergencies, and recommendations to address any gaps       identified in such workforce.        (2) Contents.--The Comptroller General shall include in the       report under paragraph (1)--        (A) the number of health care providers who have       volunteered to provide health care services during a public       health emergency, including members of the National Disaster       Medical System, the Disaster Medical Assistant Teams, the       Medical Reserve Corps, and other volunteer health care       professionals in the verification network pursuant to section       319I of the Public Health Service Act (42 U.S.C. 247d-7b);        (B) the capacity of the workforce described in subparagraph       (A) to respond to a public health emergency or potential       public health emergency, including the capacity to respond to       multiple concurrent public health emergencies and the       capacity to respond to a nationwide public health emergency;        (C) the preparedness and response capabilities and mission       readiness of the workforce described in subparagraph (A)       taking into account areas of health care expertise and       considerations for at-risk individuals (as defined in section       2802(b)(4)(B) of the Public Health Service Act (42 U.S.C.       300hh-1(b)(4)(B)));        (D) an assessment of the effectiveness of efforts to       recruit, retain, and train such workforce; and        (E) identification of gaps that may exist in such workforce       and recommendations for addressing such gaps, the extent to       which the Assistant Secretary for Preparedness and Response       plans to address such gaps, and any recommendations from the       Comptroller General to address such gaps.       SEC. 302. HEALTH SYSTEM INFRASTRUCTURE TO IMPROVE                     PREPAREDNESS AND RESPONSE.         (a) Coordination of Preparedness.--Section 2811(b)(5) (42       U.S.C. 300hh-10(b)(5)) is amended by adding at the end the       following: ``Such logistical support shall include working       with other relevant Federal, State, local, tribal, and       territorial public health officials and private sector       entities to identify the critical infrastructure assets,       systems, and networks needed for the proper functioning of       the health care and public health sectors that need to be       maintained through any emergency or disaster, including       entities capable of assisting with, responding to, and       mitigating the effect of a public health emergency, including       a public health emergency determined by the Secretary       pursuant to section 319(a) or an emergency or major disaster       declared by the President under the Robert T. Stafford       Disaster Relief and Emergency Assistance Act or the National       Emergencies Act, including by establishing methods to       exchange critical information and deliver products consumed       or used to preserve, protect, or sustain life, health, or       safety, and sharing of specialized expertise.''.        (b) Manufacturing Capacity.--Section 2811(d)(2)(C) (42       U.S.C. 300hh-10(d)(2)(C)) is amended by inserting ``, and       ancillary medical supplies to assist with the utilization of       such countermeasures or products,'' after ``products''.        (c) Evaluation of Barriers to Rapid Delivery of Medical       Countermeasures.--        (1) Rapid delivery study.--The Assistant Secretary for       Preparedness and Response may conduct a study on issues that       have the potential to adversely affect the handling and rapid       delivery of medical countermeasures to individuals during       public health emergencies occurring in the United States.        (2) Notice to congress.--Not later than 9 months after the       date of the enactment of this Act, the Assistant Secretary       for Preparedness and Response shall notify the Committee on       Energy and Commerce of the House of Representatives and the       Committee on Health, Education, Labor, and Pensions of the       Senate if the Assistant Secretary for Preparedness and       Response does not plan to conduct the study under paragraph       (1) and shall provide such committees a summary explanation       for such decision.        (3) Report to congress.--Not later than 1 year after the       Assistant Secretary for Preparedness and Response conducts       the study under paragraph (1), such Assistant Secretary shall       submit a report to the Committee on Energy and Commerce of       the House of Representatives and the Committee on Health,       Education, Labor, and Pensions of the Senate containing the       findings of such study.       SEC. 303. CONSIDERATIONS FOR AT-RISK INDIVIDUALS.         (a) At-risk Individuals in the National Health Security       Strategy.--Section 2802(b)(4)(B) (42 U.S.C. 300hh-1(b)(4)(B))       is amended--        (1) by striking ``this section and sections 319C-1, 319F,       and 319L,'' and inserting ``this Act,''; and        (2) by striking ``special'' and inserting ``access or       functional''.        (b) Countermeasure Considerations.--Section 319L(c)(6) (42       U.S.C. 247d-7e(c)(6)) is amended--        (1) by striking ``elderly'' and inserting ``older adults'';       and        (2) by inserting ``with relevant characteristics that       warrant consideration during the process of researching and       developing such countermeasures and products'' before the       period.        (c) Biosurveillance of Emerging Public Health Threats.--      Section 2814 is amended--        (1) in paragraph (7), by striking ``; and'' and inserting a       semicolon;        (2) in paragraph (8), by striking the period and inserting       ``; and''; and        (3) by adding at the end the following:        ``(9) facilitate coordination to ensure that, in       implementing the situational awareness and biosurveillance       network under section 319D, the Secretary considers       incorporating data and information from Federal, State,       local, tribal, and territorial public health officials and       entities relevant to detecting emerging public health threats       that may affect at-risk individuals, such as pregnant and       postpartum women and infants, including adverse health       outcomes of such populations related to such emerging public       health threats.''.       SEC. 304. IMPROVING EMERGENCY PREPAREDNESS AND RESPONSE                     CONSIDERATIONS FOR CHILDREN.         Part B of title III (42 U.S.C. 243 et seq.) is amended by       inserting after section 319D the following:       ``SEC. 319D-1. CHILDREN'S PREPAREDNESS UNIT.         ``(a) Enhancing Emergency Preparedness for Children.--The       Secretary, acting through the Director of the Centers for       Disease Control and Prevention (referred to in this       subsection as the `Director'), shall maintain an internal       team of experts, to be known as the Children's Preparedness       Unit (referred to in this subsection as the `Unit'), to work       collaboratively to provide guidance on the considerations       for, and the specific needs of, children before, during, and       after public health emergencies. The Unit shall inform the       Director regarding emergency preparedness and response       efforts pertaining to children at the Centers for Disease       Control and Prevention.        ``(b) Expertise.--The team described in subsection (a)       shall include one or more pediatricians, which may be a       developmental-behavioral pediatrician, and may also include       behavioral scientists, child psychologists, epidemiologists,       biostatisticians, health communications staff, and       individuals with other areas of expertise, as the Secretary       determines appropriate.        ``(c) Duties.--The team described in subsection (a) may--        ``(1) assist State, local, tribal, and territorial       emergency planning and response activities related to       children, which may include developing, identifying, and       sharing best practices;        ``(2) provide technical assistance, training, and       consultation to Federal, State, local, tribal, and       territorial public health officials to improve preparedness       and response capabilities with respect to the needs of       children, including providing such technical assistance,       training, and consultation to eligible entities in order to       support the achievement of measurable evidence-based       benchmarks and objective standards applicable to sections       319C-1 and 319C-2;        ``(3) improve the utilization of methods to incorporate the       needs of children in planning for and responding to a public       health emergency, including public awareness of such methods;  [[Page H10375]]         ``(4) coordinate with, and improve, public-private       partnerships, such as health care coalitions pursuant to       sections 319C-2 and 319C-3, to address gaps and       inefficiencies in emergency preparedness and response efforts       for children;        ``(5) provide expertise and input during the development of       guidance and clinical recommendations to address the needs of       children when preparing for, and responding to, public health       emergencies, including pursuant to section 319C-3; and        ``(6) carry out other duties related to preparedness and       response activities for children, as the Secretary determines       appropriate.''.       SEC. 305. NATIONAL ADVISORY COMMITTEES ON DISASTERS.         (a) Reauthorizing the National Advisory Committee on       Children and Disasters.--Section 2811A (42 U.S.C. 300hh-10a)       is amended--        (1) in subsection (b)(2), by inserting ``, mental and       behavioral,'' after ``medical'';        (2) in subsection (d)--        (A) in paragraph (1), by striking ``15'' and inserting       ``25''; and        (B) by striking paragraph (2) and inserting the following:        ``(2) Required non-federal members.--The Secretary, in       consultation with such other heads of Federal agencies as may       be appropriate, shall appoint to the Advisory Committee under       paragraph (1) at least 13 individuals, including--        ``(A) at least 2 non-Federal professionals with expertise       in pediatric medical disaster planning, preparedness,       response, or recovery;        ``(B) at least 2 representatives from State, local, tribal,       or territorial agencies with expertise in pediatric disaster       planning, preparedness, response, or recovery;        ``(C) at least 4 members representing health care       professionals, which may include members with expertise in       pediatric emergency medicine; pediatric trauma, critical       care, or surgery; the treatment of pediatric patients       affected by chemical, biological, radiological, or nuclear       agents, including emerging infectious diseases; pediatric       mental or behavioral health related to children affected by a       public health emergency; or pediatric primary care; and        ``(D) other members as the Secretary determines       appropriate, of whom--        ``(i) at least one such member shall represent a children's       hospital;        ``(ii) at least one such member shall be an individual with       expertise in schools or child care settings;        ``(iii) at least one such member shall be an individual       with expertise in children and youth with special health care       needs; and        ``(iv) at least one such member shall be an individual with       expertise in the needs of parents or family caregivers,       including the parents or caregivers of children with       disabilities.''.        ``(3) Federal members.--The Advisory Committee under       paragraph (1) shall include the following Federal members or       their designees (who may be non-voting members, as determined       by the Secretary):        ``(A) The Assistant Secretary for Preparedness and       Response.        ``(B) The Director of the Biomedical Advanced Research and       Development Authority.        ``(C) The Director of the Centers for Disease Control and       Prevention.        ``(D) The Commissioner of Food and Drugs.        ``(E) The Director of the National Institutes of Health.        ``(F) The Assistant Secretary of the Administration for       Children and Families.        ``(G) The Administrator of the Health Resources and       Services Administration.        ``(H) The Administrator of the Federal Emergency Management       Agency.        ``(I) The Administrator of the Administration for Community       Living.        ``(J) The Secretary of Education.        ``(K) Representatives from such Federal agencies (such as       the Substance Abuse and Mental Health Services Administration       and the Department of Homeland Security) as the Secretary       determines appropriate to fulfill the duties of the Advisory       Committee under subsections (b) and (c).''.        ``(4) Term of appointment.--Each member of the Advisory       Committee appointed under paragraph (2) shall serve for a       term of 3 years, except that the Secretary may adjust the       terms of the Advisory Committee appointees serving on the       date of enactment of the Pandemic and All-Hazards       Preparedness and Advancing Innovation Act of 2018, or       appointees who are initially appointed after such date of       enactment, in order to provide for a staggered term of       appointment for all members.        ``(5) Consecutive appointments; maximum terms.--A member       appointed under paragraph (2) may serve not more than 3 terms       on the Advisory Committee, and not more than 2 of such terms       may be served consecutively.'';        (3) in subsection (e), by adding at the end ``At least one       meeting per year shall be an in-person meeting.'';        (4) by redesignating subsection (f) as subsection (g);        (5) by inserting after subsection (e) the following:        ``(f) Coordination.--The Secretary shall coordinate duties       and activities authorized under this section in accordance       with section 2811D.''; and        (6) in subsection (g), as so redesignated, by striking       ``2018'' and inserting ``2023''.        (b) Authorizing the National Advisory Committee on Seniors       and Disasters.--Subtitle B of title XXVIII (42 U.S.C. 300hh       et seq.) is amended by inserting after section 2811A the       following:       ``SEC. 2811B. NATIONAL ADVISORY COMMITTEE ON SENIORS AND                     DISASTERS.         ``(a) Establishment.--The Secretary, in consultation with       the Secretary of Homeland Security and the Secretary of       Veterans Affairs, shall establish an advisory committee to be       known as the National Advisory Committee on Seniors and       Disasters (referred to in this section as the `Advisory       Committee').        ``(b) Duties.--The Advisory Committee shall--        ``(1) provide advice and consultation with respect to the       activities carried out pursuant to section 2814, as       applicable and appropriate;        ``(2) evaluate and provide input with respect to the       medical and public health needs of seniors related to       preparation for, response to, and recovery from all-hazards       emergencies; and        ``(3) provide advice and consultation with respect to State       emergency preparedness and response activities relating to       seniors, including related drills and exercises pursuant to       the preparedness goals under section 2802(b).        ``(c) Additional Duties.--The Advisory Committee may       provide advice and recommendations to the Secretary with       respect to seniors and the medical and public health grants       and cooperative agreements as applicable to preparedness and       response activities under this title and title III.        ``(d) Membership.--        ``(1) In general.--The Secretary, in consultation with such       other heads of agencies as appropriate, shall appoint not       more than 17 members to the Advisory Committee. In appointing       such members, the Secretary shall ensure that the total       membership of the Advisory Committee is an odd number.        ``(2) Required members.--The Advisory Committee shall       include Federal members or their designees (who may be non-      voting members, as determined by the Secretary) and non-      Federal members, as follows:        ``(A) The Assistant Secretary for Preparedness and       Response.        ``(B) The Director of the Biomedical Advanced Research and       Development Authority.        ``(C) The Director of the Centers for Disease Control and       Prevention.        ``(D) The Commissioner of Food and Drugs.        ``(E) The Director of the National Institutes of Health.        ``(F) The Administrator of the Centers for Medicare &       Medicaid Services.        ``(G) The Administrator of the Administration for Community       Living.        ``(H) The Administrator of the Federal Emergency Management       Agency.        ``(I) The Under Secretary for Health of the Department of       Veterans Affairs.        ``(J) At least 2 non-Federal health care professionals with       expertise in geriatric medical disaster planning,       preparedness, response, or recovery.        ``(K) At least 2 representatives of State, local, tribal,       or territorial agencies with expertise in geriatric disaster       planning, preparedness, response, or recovery.        ``(L) Representatives of such other Federal agencies (such       as the Department of Energy and the Department of Homeland       Security) as the Secretary determines necessary to fulfill       the duties of the Advisory Committee.        ``(e) Meetings.--The Advisory Committee shall meet not less       frequently than biannually. At least one meeting per year       shall be an in-person meeting.        ``(f) Coordination.--The Secretary shall coordinate duties       and activities authorized under this section in accordance       with section 2811D.        ``(g) Sunset.--        ``(1) In general.--The Advisory Committee shall terminate       on September 30, 2023.        ``(2) Extension of committee.--Not later than October 1,       2022, the Secretary shall submit to Congress a recommendation       on whether the Advisory Committee should be extended.''.        (c) National Advisory Committee on Individuals With       Disabilities and Disasters.--Subtitle B of title XXVIII (42       U.S.C. 300hh et seq.), as amended by subsection (b), is       further amended by inserting after section 2811B the       following:       ``SEC. 2811C. NATIONAL ADVISORY COMMITTEE ON INDIVIDUALS WITH                     DISABILITIES AND DISASTERS.         ``(a) Establishment.--The Secretary, in consultation with       the Secretary of Homeland Security, shall establish a       national advisory committee to be known as the National       Advisory Committee on Individuals with Disabilities and       Disasters (referred to in this section as the `Advisory       Committee').        ``(b) Duties.--The Advisory Committee shall--        ``(1) provide advice and consultation with respect to       activities carried out pursuant to section 2814, as       applicable and appropriate;        ``(2) evaluate and provide input with respect to the       medical, public health, and accessibility needs of       individuals with disabilities related to preparation for,       response to, and recovery from all-hazards emergencies; and        ``(3) provide advice and consultation with respect to State       emergency preparedness and response activities, including       related drills and exercises pursuant to the preparedness       goals under section 2802(b).        ``(c) Membership.--        ``(1) In general.--The Secretary, in consultation with such       other heads of agencies  [[Page H10376]]       and departments as appropriate, shall appoint not more than       17 members to the Advisory Committee. In appointing such       members, the Secretary shall ensure that the total membership       of the Advisory Committee is an odd number.        ``(2) Required members.--The Advisory Committee shall       include Federal members or their designees (who may be non-      voting members, as determined by the Secretary) and non-      Federal members, as follows:        ``(A) The Assistant Secretary for Preparedness and       Response.        ``(B) The Administrator of the Administration for Community       Living.        ``(C) The Director of the Biomedical Advanced Research and       Development Authority.        ``(D) The Director of the Centers for Disease Control and       Prevention.        ``(E) The Commissioner of Food and Drugs.        ``(F) The Director of the National Institutes of Health.        ``(G) The Administrator of the Federal Emergency Management       Agency.        ``(H) The Chair of the National Council on Disability.        ``(I) The Chair of the United States Access Board.        ``(J) The Under Secretary for Health of the Department of       Veterans Affairs.        ``(K) At least 2 non-Federal health care professionals with       expertise in disability accessibility before, during, and       after disasters, medical and mass care disaster planning,       preparedness, response, or recovery.        ``(L) At least 2 representatives from State, local, tribal,       or territorial agencies with expertise in disaster planning,       preparedness, response, or recovery for individuals with       disabilities.        ``(M) At least 2 individuals with a disability with       expertise in disaster planning, preparedness, response, or       recovery for individuals with disabilities.        ``(d) Meetings.--The Advisory Committee shall meet not less       frequently than biannually. At least one meeting per year       shall be an in-person meeting.        ``(e) Disability Defined.--For purposes of this section,       the term `disability' has the meaning given such term in       section 3 of the Americans with Disabilities Act of 1990.        ``(f) Coordination.--The Secretary shall coordinate duties       and activities authorized under this section in accordance       with section 2811D.        ``(g) Sunset.--        ``(1) In general.--The Advisory Committee shall terminate       on September 30, 2023.        ``(2) Recommendation.--Not later than October 1, 2022, the       Secretary shall submit to Congress a recommendation on       whether the Advisory Committee should be extended.''.        (d) Advisory Committee Coordination.--Subtitle B of title       XXVIII (42 U.S.C. 300hh et seq.), as amended by subsection       (c), is further amended by inserting after section 2811C the       following:       ``SEC. 2811D. ADVISORY COMMITTEE COORDINATION.         ``(a) In General.--The Secretary shall coordinate duties       and activities authorized under sections 2811A, 2811B, and       2811C, and make efforts to reduce unnecessary or duplicative       reporting, or unnecessary duplicative meetings and       recommendations under such sections, as practicable. Members       of the advisory committees authorized under such sections, or       their designees, shall annually meet to coordinate any       recommendations, as appropriate, that may be similar,       duplicative, or overlapping with respect to addressing the       needs of children, seniors, and individuals with disabilities       during public health emergencies. If such coordination occurs       through an in-person meeting, it shall not be considered the       required in-person meetings under any of sections 2811A(e),       2811B(e), or 2811C(d).        ``(b) Coordination and Alignment.--The Secretary, acting       through the employee designated pursuant to section 2814,       shall align preparedness and response programs or activities       to address similar, dual, or overlapping needs of children,       seniors, and individuals with disabilities, and any       challenges in preparing for and responding to such needs.        ``(c) Notification.--The Secretary shall annually notify       the congressional committees of jurisdiction regarding the       steps taken to coordinate, as appropriate, the       recommendations under this section, and provide a summary       description of such coordination.''.       SEC. 306. GUIDANCE FOR PARTICIPATION IN EXERCISES AND DRILLS.         Not later than 2 years after the date of enactment of this       Act, the Secretary of Health and Human Services shall issue       final guidance regarding the ability of personnel funded by       programs authorized under this Act (including the amendments       made by this Act) to participate in drills and operational       exercises related to all-hazards medical and public health       preparedness and response. Such drills and operational       exercises may include activities that incorporate medical       surge capacity planning, medical countermeasure distribution       and administration, and preparing for and responding to       identified threats for that region. Such personnel may       include State, local, tribal, and territorial public health       department or agency personnel funded under this Act       (including the amendments made by this Act). The Secretary       shall consult with the Department of Homeland Security, the       Department of Defense, the Department of Veterans Affairs,       and other applicable Federal departments and agencies as       necessary and appropriate in the development of such       guidance. The Secretary shall make the guidance available on       the internet website of the Department of Health and Human       Services.               TITLE IV--PRIORITIZING A THREAT-BASED APPROACH       SEC. 401. ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.         Section 2811(b) (42 U.S.C. 300hh-10(b)) is amended--        (1) in the matter preceding paragraph (1) by inserting       ``utilize experience related to public health emergency       preparedness and response, biodefense, medical       countermeasures, and other relevant topics to'' after       ``shall''; and        (2) in paragraph (4) by adding at the end the following:        ``(I) Threat awareness.--Coordinate with the Director of       the Centers for Disease Control and Prevention, the Director       of National Intelligence, the Secretary of Homeland Security,       the Assistant to the President for National Security Affairs,       the Secretary of Defense, and other relevant Federal       officials, such as the Secretary of Agriculture, to maintain       a current assessment of national security threats and inform       preparedness and response capabilities based on the range of       the threats that have the potential to result in a public       health emergency.''.       SEC. 402. PUBLIC HEALTH EMERGENCY MEDICAL COUNTERMEASURES                     ENTERPRISE.         (a) In General.--Title XXVIII is amended by inserting after       section 2811 (42 U.S.C. 300hh-10) the following:       ``SEC. 2811-1. PUBLIC HEALTH EMERGENCY MEDICAL                     COUNTERMEASURES ENTERPRISE.         ``(a) In General.--The Secretary shall establish the Public       Health Emergency Medical Countermeasures Enterprise (referred       to in this section as the `PHEMCE'). The Assistant Secretary       for Preparedness and Response shall serve as chair of the       PHEMCE.        ``(b) Members.--The PHEMCE shall include each of the       following members, or the designee of such members:        ``(1) The Assistant Secretary for Preparedness and       Response.        ``(2) The Director of the Centers for Disease Control and       Prevention.        ``(3) The Director of the National Institutes of Health.        ``(4) The Commissioner of Food and Drugs.        ``(5) The Secretary of Defense.        ``(6) The Secretary of Homeland Security.        ``(7) The Secretary of Agriculture.        ``(8) The Secretary of Veterans Affairs.        ``(9) The Director of National Intelligence.        ``(10) Representatives of any other Federal agency, which       may include the Director of the Biomedical Advanced Research       and Development Authority, the Director of the Strategic       National Stockpile, the Director of the National Institute of       Allergy and Infectious Diseases, and the Director of the       Office of Public Health Preparedness and Response, as the       Secretary determines appropriate.        ``(c) Functions.--        ``(1) In general.--The functions of the PHEMCE shall       include the following:        ``(A) Utilize a process to make recommendations to the       Secretary regarding research, advanced research, development,       procurement, stockpiling, deployment, distribution, and       utilization with respect to countermeasures, as defined in       section 319F-2(c), including prioritization based on the       health security needs of the United States. Such       recommendations shall be informed by, when available and       practicable, the National Health Security Strategy pursuant       to section 2802, the Strategic National Stockpile needs       pursuant to section 319F-2, and assessments of current       national security threats, including chemical, biological,       radiological, and nuclear threats, including emerging       infectious diseases. In the event that members of the PHEMCE       do not agree upon a recommendation, the Secretary shall       provide a determination regarding such recommendation.        ``(B) Identify national health security needs, including       gaps in public health preparedness and response related to       countermeasures and challenges to addressing such needs       (including any regulatory challenges), and support alignment       of countermeasure procurement with recommendations to address       such needs under subparagraph (A).        ``(C) Assist the Secretary in developing strategies related       to logistics, deployment, distribution, dispensing, and use       of countermeasures that may be applicable to the activities       of the strategic national stockpile under section 319F-2(a).        ``(D) Provide consultation for the development of the       strategy and implementation plan under section 2811(d).        ``(2) Input.--In carrying out subparagraphs (B) and (C) of       paragraph (1), the PHEMCE shall solicit and consider input       from State, local, tribal, and territorial public health       departments or officials, as appropriate.''.        (b) Public Health Emergency Medical Countermeasures       Enterprise Strategy and Implementation Plan.--Section 2811(d)       (42 U.S.C. 300hh-10(d)) is amended--        (1) in paragraph (1)--        (A) by striking ``Not later than 180 days after the date of       enactment of this subsection, and every year thereafter'' and       inserting ``Not later than March 15, 2020, and biennially       thereafter''; and        (B) by striking ``Director of the Biomedical'' and all that       follows through ``Food and Drugs'' and inserting ``Public       Health Emergency Medical Countermeasures Enterprise       established under section 2811-1''; and        (2) in paragraph (2)(J)(v), by striking ``one-year period''       and inserting ``2-year period''.  [[Page H10377]]            SEC. 403. STRATEGIC NATIONAL STOCKPILE.         (a) In General.--Section 319F-2(a) (42 U.S.C. 247d-6b(a))       is amended--        (1) by redesignating paragraphs (2) and (3) as paragraphs       (3) and (4), respectively; and        (2) in paragraph (1)--        (A) by inserting ``the Assistant Secretary for Preparedness       and Response and'' after ``collaboration with'';        (B) by inserting ``and optimize'' after ``provide for'';        (C) by inserting ``and, as informed by existing       recommendations of, or consultations with, the Public Health       Emergency Medical Countermeasure Enterprise established under       section 2811-1, make necessary additions or modifications to       the contents of such stockpile or stockpiles based on the       review conducted under paragraph (2)'' before the period of       the first sentence; and        (D) by striking the second sentence;        (3) by inserting after paragraph (1) the following:        ``(2) Threat-based review.--        ``(A) In general.--The Secretary shall conduct an annual       threat-based review (taking into account at-risk individuals)       of the contents of the stockpile under paragraph (1),       including non-pharmaceutical supplies, and, in consultation       with the Public Health Emergency Medical Countermeasures       Enterprise established under section 2811-1, review contents       within the stockpile and assess whether such contents are       consistent with the recommendations made pursuant to section       2811-1(c)(1)(A). Such review shall be submitted on June 15,       2019, and on March 15 of each year thereafter, to the       Committee on Health, Education, Labor, and Pensions and the       Committee on Appropriations of the Senate and the Committee       on Energy and Commerce and the Committee on Appropriations of       the House of Representatives, in a manner that does not       compromise national security.        ``(B) Additions, modifications, and replenishments.--Each       annual threat-based review under subparagraph (A) shall, for       each new or modified countermeasure procurement or       replenishment, provide--        ``(i) information regarding--         ``(I) the quantities of the additional or modified       countermeasure procured for, or contracted to be procured       for, the stockpile;        ``(II) planning considerations for appropriate       manufacturing capacity and capability to meet the goals of       such additions or modifications (without disclosing       proprietary information), including consideration of the       effect such additions or modifications may have on the       availability of such products and ancillary medical supplies       in the health care system;        ``(III) the presence or lack of a commercial market for the       countermeasure at the time of procurement;        ``(IV) the emergency health security threat or threats such       countermeasure procurement is intended to address, including       whether such procurement is consistent with meeting emergency       health security needs associated with such threat or threats;        ``(V) an assessment of whether the emergency health       security threat or threats described in subclause (IV) could       be addressed in a manner that better utilizes the resources       of the stockpile and permits the greatest possible increase       in the level of emergency preparedness to address such       threats;        ``(VI) whether such countermeasure is replenishing an       expiring or expired countermeasure, is a different       countermeasure with the same indication that is replacing an       expiring or expired countermeasure, or is a new addition to       the stockpile;        ``(VII) a description of how such additions or       modifications align with projected investments under previous       countermeasures budget plans under section 2811(b)(7),       including expected life-cycle costs, expenditures related to       countermeasure procurement to address the threat or threats       described in subclause (IV), replenishment dates (including       the ability to extend the maximum shelf life of a       countermeasure), and the manufacturing capacity required to       replenish such countermeasure; and        ``(VIII) appropriate protocols and processes for the       deployment, distribution, or dispensing of the countermeasure       at the State and local level, including plans for relevant       capabilities of State and local entities to dispense,       distribute, and administer the countermeasure; and         ``(ii) an assurance, which need not be provided in advance       of procurement, that for each countermeasure procured or       replenished under this subsection, the Secretary completed a       review addressing each item listed under this subsection in       advance of such procurement or replenishment.'';        (4) in paragraph (3), as so redesignated--        (A) in subparagraph (A), by inserting ``and the Public       Health Emergency Medical Countermeasures Enterprise       established under section 2811-1'' before the semicolon;        (B) in subparagraph (C), by inserting ``, and the       availability, deployment, dispensing, and administration of       countermeasures'' before the semicolon;        (C) by amending subparagraph (E) to read as follows:        ``(E) devise plans for effective and timely supply-chain       management of the stockpile, in consultation with the       Director of the Centers for Disease Control and Prevention,       the Assistant Secretary for Preparedness and Response, the       Secretary of Transportation, the Secretary of Homeland       Security, the Secretary of Veterans Affairs, and the heads of       other appropriate Federal agencies; State, local, tribal, and       territorial agencies; and the public and private health care       infrastructure, as applicable, taking into account the       manufacturing capacity and other available sources of       products and appropriate alternatives to supplies in the       stockpile;'';        (D) in subparagraph (G), by striking ``; and'' and       inserting a semicolon;        (E) in subparagraph (H), by striking the period and       inserting a semicolon; and        (F) by adding at the end the following:        ``(I) ensure that each countermeasure or product under       consideration for procurement pursuant to this subsection       receives the same consideration regardless of whether such       countermeasure or product receives or had received funding       under section 319L, including with respect to whether the       countermeasure or product is most appropriate to meet the       emergency health security needs of the United States; and        ``(J) provide assistance, including technical assistance,       to maintain and improve State and local public health       preparedness capabilities to distribute and dispense medical       countermeasures and products from the stockpile, as       appropriate.''; and        (5) by adding at the end the following:        ``(5) GAO report.--        ``(A) In general.--Not later than 3 years after the date of       enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018, and every 5 years       thereafter, the Comptroller General of the United States       shall conduct a review of any changes to the contents or       management of the stockpile since January 1, 2015. Such       review shall include--        ``(i) an assessment of the comprehensiveness and       completeness of each annual threat-based review under       paragraph (2), including whether all newly procured or       replenished countermeasures within the stockpile were       described in each annual review, and whether, consistent with       paragraph (2)(B), the Secretary conducted the necessary       internal review in advance of such procurement or       replenishment;        ``(ii) an assessment of whether the Secretary established       health security and science-based justifications, and a       description of such justifications for procurement decisions       related to health security needs with respect to the       identified threat, for additions or modifications to the       stockpile based on the information provided in such reviews       under paragraph (2)(B), including whether such review was       conducted prior to procurement, modification, or       replenishment;        ``(iii) an assessment of the plans developed by the       Secretary for the deployment, distribution, and dispensing of       countermeasures procured, modified, or replenished under       paragraph (1), including whether such plans were developed       prior to procurement, modification, or replenishment;        ``(iv) an accounting of countermeasures procured, modified,       or replenished under paragraph (1) that received advanced       research and development funding from the Biomedical Advanced       Research and Development Authority;        ``(v) an analysis of how such procurement decisions made       progress toward meeting emergency health security needs       related to the identified threats for countermeasures added,       modified, or replenished under paragraph (1);        ``(vi) a description of the resources expended related to       the procurement of countermeasures (including additions,       modifications, and replenishments) in the stockpile, and how       such expenditures relate to the ability of the stockpile to       meet emergency health security needs;        ``(vii) an assessment of the extent to which additions,       modifications, and replenishments reviewed under paragraph       (2) align with previous relevant reports or reviews by the       Secretary or the Comptroller General;        ``(viii) with respect to any change in the Federal       organizational management of the stockpile, an assessment and       comparison of the processes affected by such change,       including planning for potential countermeasure deployment,       distribution, or dispensing capabilities and processes       related to procurement decisions, use of stockpiled       countermeasures, and use of resources for such activities;       and        ``(ix) an assessment of whether the processes and       procedures described by the Secretary pursuant to section       403(b) of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018 are sufficient to ensure       countermeasures and products under consideration for       procurement pursuant to subsection (a) receive the same       consideration regardless of whether such countermeasures and       products receive or had received funding under section 319L,       including with respect to whether such countermeasures and       products are most appropriate to meet the emergency health       security needs of the United States.        ``(B) Submission.--Not later than 6 months after completing       a classified version of the review under subparagraph (A),       the Comptroller General shall submit an unclassified version       of the review to the congressional committees of       jurisdiction.''.        (b) Additional Reporting.--In the first threat-based review       submitted after the date of enactment of this Act pursuant to       paragraph (2) of section 319F-2(a) of the Public Health       Service Act (42 U.S.C. 247d-6b(a)), as amended by subsection       (a), the Secretary shall include a description of the       processes and procedures through which the Director of       Strategic National Stockpile and the Director of the       Biomedical Advanced Research and Development Authority       coordinate with  [[Page H10378]]       respect to countermeasures and products procured under such       section 319F-2(a), including such processes and procedures in       place to ensure countermeasures and products under       consideration for procurement pursuant to such section 319F-      2(a) receive the same consideration regardless of whether       such countermeasures or products receive or had received       funding under section 319L of the Public Health Service Act       (42 U.S.C. 247d-7e), and whether such countermeasures and       products are the most appropriate to meet the emergency       health security needs of the United States.        (c) Authorization of Appropriations, Strategic National       Stockpile.--Section 319F-2(f)(1) (42 U.S.C. 247d-6b(f)(1)) is       amended by striking ``$533,800,000 for each of fiscal years       2014 through 2018'' and inserting ``$610,000,000 for each of       fiscal years 2019 through 2023, to remain available until       expended''.       SEC. 404. PREPARING FOR PANDEMIC INFLUENZA, ANTIMICROBIAL                     RESISTANCE, AND OTHER SIGNIFICANT THREATS.         (a) Strategic Initiatives.--Section 319L(c)(4) (247d-      7e(c)(4)) is amended by adding at the end the following:        ``(F) Strategic initiatives.--The Secretary, acting through       the Director of BARDA, may implement strategic initiatives,       including by building on existing programs and by awarding       contracts, grants, and cooperative agreements, or entering       into other transactions, to support innovative candidate       products in preclinical and clinical development that address       priority, naturally occurring and man-made threats that, as       determined by the Secretary, pose a significant level of risk       to national security based on the characteristics of a       chemical, biological, radiological or nuclear threat, or       existing capabilities to respond to such a threat (including       medical response and treatment capabilities and manufacturing       infrastructure). Such initiatives shall accelerate and       support the advanced research, development, and procurement       of, countermeasures and products, as applicable, to address       areas including--        ``(i) chemical, biological, radiological, or nuclear       threats, including emerging infectious diseases, for which       insufficient approved, licensed, or authorized       countermeasures exist, or for which such threat, or the       result of an exposure to such threat, may become resistant to       countermeasures or existing countermeasures may be rendered       ineffective;        ``(ii) threats that consistently exist or continually       circulate and have a significant potential to become a       pandemic, such as pandemic influenza, which may include the       advanced research and development, manufacturing, and       appropriate stockpiling of qualified pandemic or epidemic       products, and products, technologies, or processes to support       the advanced research and development of such countermeasures       (including multiuse platform technologies for diagnostics,       vaccines, and therapeutics; virus seeds; clinical trial lots;       novel virus strains; and antigen and adjuvant material); and        ``(iii) threats that may result primarily or secondarily       from a chemical, biological, radiological, or nuclear agent,       or emerging infectious diseases, and which may present       increased treatment complications such as the occurrence of       resistance to available countermeasures or potential       countermeasures, including antimicrobial resistant       pathogens.''.        (b) Protection of National Security From Threats.--Section       2811 (42 U.S.C. 300hh-10) is amended by adding at the end the       following:        ``(f) Protection of National Security From Threats.--        ``(1) In general.--In carrying out subsection (b)(3), the       Assistant Secretary for Preparedness and Response shall       implement strategic initiatives or activities to address       threats, including pandemic influenza and which may include a       chemical, biological, radiological, or nuclear agent       (including any such agent with a significant potential to       become a pandemic), that pose a significant level of risk to       public health and national security based on the       characteristics of such threat. Such initiatives shall       include activities to--        ``(A) accelerate and support the advanced research,       development, manufacturing capacity, procurement, and       stockpiling of countermeasures, including initiatives under       section 319L(c)(4)(F);        ``(B) support the development and manufacturing of virus       seeds, clinical trial lots, and stockpiles of novel virus       strains; and        ``(C) maintain or improve preparedness activities,       including for pandemic influenza.        ``(2) Authorization of appropriations.--        ``(A) In general.--To carry out this subsection, there is       authorized to be appropriated $250,000,000 for each of fiscal       years 2019 through 2023.        ``(B) Supplement, not supplant.--Amounts appropriated under       this paragraph shall be used to supplement and not supplant       funds provided under sections 319L(d) and 319F-2(g).        ``(C) Documentation required.--The Assistant Secretary for       Preparedness and Response, in accordance with subsection       (b)(7), shall document amounts expended for purposes of       carrying out this subsection, including amounts appropriated       under the heading `Public Health and Social Services       Emergency Fund' under the heading `Office of the Secretary'       under title II of division H of the Consolidated       Appropriations Act, 2018 (Public Law 115-141) and allocated       to carrying out section 319L(c)(4)(F).''.       SEC. 405. REPORTING ON THE FEDERAL SELECT AGENT PROGRAM.         Section 351A(k) (42 U.S.C. 262a(k)) is amended--        (1) by striking ``The Secretary'' and inserting the       following:        ``(1) In general.--The Secretary''; and        (2) by adding at the end the following:        ``(2) Implementation of recommendations of the federal       experts security advisory panel and the fast track action       committee on select agent regulations.--        ``(A) In general.--Not later than 1 year after the date of       the enactment of the Pandemic and All-Hazards Preparedness       and Advancing Innovation Act of 2018, the Secretary shall       report to the congressional committees of jurisdiction on the       implementation of recommendations of the Federal Experts       Security Advisory Panel concerning the select agent program.        ``(B) Continued updates.--The Secretary shall report to the       congressional committees of jurisdiction annually following       the submission of the report under subparagraph (A) until the       recommendations described in such subparagraph are fully       implemented, or a justification is provided for the delay in,       or lack of, implementation.''.   TITLE V--INCREASING COMMUNICATION IN MEDICAL COUNTERMEASURE ADVANCED                          RESEARCH AND DEVELOPMENT       SEC. 501. MEDICAL COUNTERMEASURE BUDGET PLAN.         Section 2811(b)(7) (42 U.S.C. 300hh-10(b)(7)) is amended--        (1) in the matter preceding subparagraph (A), by striking       ``March 1'' and inserting ``March 15'';        (2) in subparagraph (A)--        (A) in clause (ii), by striking ``; and'' and inserting       ``;''; and        (B) by striking clause (iii) and inserting the following:        ``(iii) procurement, stockpiling, maintenance, and       potential replenishment (including manufacturing       capabilities) of all products in the Strategic National       Stockpile;        ``(iv) the availability of technologies that may assist in       the advanced research and development of countermeasures and       opportunities to use such technologies to accelerate and       navigate challenges unique to countermeasure research and       development; and        ``(v) potential deployment, distribution, and utilization       of medical countermeasures; development of clinical guidance       and emergency use instructions for the use of medical       countermeasures; and, as applicable, potential post-      deployment activities related to medical countermeasures;'';        (3) by redesignating subparagraphs (D) and (E) as       subparagraphs (E) and (F), respectively; and        (4) by inserting after subparagraph (C), the following:        ``(D) identify the full range of anticipated medical       countermeasure needs related to research and development,       procurement, and stockpiling, including the potential need       for indications, dosing, and administration technologies, and       other countermeasure needs as applicable and appropriate;''.       SEC. 502. MATERIAL THREAT AND MEDICAL COUNTERMEASURE                     NOTIFICATIONS.         (a) Congressional Notification of Material Threat       Determination.--Section 319F-2(c)(2)(C) (42 U.S.C. 247d-      6b(c)(2)(C)) is amended by striking ``The Secretary and the       Homeland Security Secretary shall promptly notify the       appropriate committees of Congress'' and inserting ``The       Secretary and the Secretary of Homeland Security shall send       to Congress, on an annual basis, all current material threat       determinations and shall promptly notify the Committee on       Health, Education, Labor, and Pensions and the Committee on       Homeland Security and Governmental Affairs of the Senate and       the Committee on Energy and Commerce and the Committee on       Homeland Security of the House of Representatives''.        (b) Contracting Communication.--Section 319F-      2(c)(7)(B)(ii)(III) (42 U.S.C. 247d-6b(c)(7)(B)(ii)(III)) is       amended by adding at the end the following: ``The Secretary       shall notify the vendor within 90 days of a determination by       the Secretary to renew, extend, or terminate such       contract.''.       SEC. 503. AVAILABILITY OF REGULATORY MANAGEMENT PLANS.         Section 565(f) of the Federal Food, Drug, and Cosmetic Act       (21 U.S.C. 360bbb-4(f)) is amended--        (1) by redesignating paragraphs (3) through (6) as       paragraphs (4) through (7), respectively;        (2) by inserting after paragraph (2) the following:        ``(3) Publication.--The Secretary shall make available on       the internet website of the Food and Drug Administration       information regarding regulatory management plans,       including--        ``(A) the process by which an applicant may submit a       request for a regulatory management plan;        ``(B) the timeframe by which the Secretary is required to       respond to such request;        ``(C) the information required for the submission of such       request;        ``(D) a description of the types of development milestones       and performance targets that could be discussed and included       in such plans; and        ``(E) contact information for beginning the regulatory       management plan process.'';        (3) in paragraph (6), as so redesignated, in the matter       preceding subparagraph (A)--  [[Page H10379]]         (A) by striking ``paragraph (4)(A)'' and inserting       ``paragraph (5)(A)''; and        (B) by striking ``paragraph (4)(B)'' and inserting       ``paragraph (5)(B)''; and        (4) in paragraph (7)(A), as so redesignated, by striking       ``paragraph (3)(A)'' and inserting ``paragraph (4)(A)''.       SEC. 504. THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT                     AUTHORITY AND THE BIOSHIELD SPECIAL RESERVE                     FUND.         (a) BioShield Special Reserve Fund.--Section 319F-2(g)(1)       (42 U.S.C. 247d-6b(g)(1)) is amended--        (1) by striking ``$2,800,000,000 for the period of fiscal       years 2014 through 2018'' and inserting ``$7,100,000,000 for       the period of fiscal years 2019 through 2028, to remain       available until expended''; and        (2) by striking the second sentence.        (b) The Biomedical Advanced Research and Development       Authority.--Section 319L(d)(2) (42 U.S.C. 247d-7e(d)(2)) is       amended by striking ``$415,000,000 for each of fiscal years       2014 through 2018'' and inserting ``$611,700,000 for each of       fiscal years 2019 through 2023''.       SEC. 505. ADDITIONAL STRATEGIES FOR COMBATING ANTIBIOTIC                     RESISTANCE.         (a) Advisory Council.--The Secretary of Health and Human       Services (referred to in this section as the ``Secretary'')       may continue the Presidential Advisory Council on Combating       Antibiotic-Resistant Bacteria, referred to in this section as       the ``Advisory Council''.        (b) Duties.--The Advisory Council shall advise and provide       information and recommendations to the Secretary regarding       programs and policies intended to reduce or combat       antibiotic-resistant bacteria that may present a public       health threat and improve capabilities to prevent, diagnose,       mitigate, or treat such resistance. Such advice, information,       and recommendations may be related to improving--        (1) the effectiveness of antibiotics;        (2) research and advanced research on, and the development       of, improved and innovative methods for combating or reducing       antibiotic resistance, including new treatments, rapid point-      of-care diagnostics, alternatives to antibiotics, including       alternatives to animal antibiotics, and antimicrobial       stewardship activities;        (3) surveillance of antibiotic-resistant bacterial       infections, including publicly available and up-to-date       information on resistance to antibiotics;        (4) education for health care providers and the public with       respect to up-to-date information on antibiotic resistance       and ways to reduce or combat such resistance to antibiotics       related to humans and animals;        (5) methods to prevent or reduce the transmission of       antibiotic-resistant bacterial infections, including       stewardship programs; and        (6) coordination with respect to international efforts in       order to inform and advance United States capabilities to       combat antibiotic resistance.        (c) Meetings and Coordination.--        (1) Meetings.--The Advisory Council shall meet not less       than biannually and, to the extent practicable, in       coordination with meetings of the Antimicrobial Resistance       Task Force established in section 319E(a) of the Public       Health Service Act.        (2) Coordination.--The Advisory Council shall, to the       greatest extent practicable, coordinate activities carried       out by the Council with the Antimicrobial Resistance Task       Force established under section 319E(a) of the Public Health       Service Act (42 U.S.C. 247d-5(a)).        (d) FACA.--The Federal Advisory Committee Act (5 U.S.C.       App.) shall apply to the activities and duties of the       Advisory Council.        (e) Extension of Advisory Council.--Not later than October       1, 2022, the Secretary shall submit to the Committee on       Health, Education, Labor, and Pensions of the Senate and the       Committee on Energy and Commerce of the House of       Representatives a recommendation on whether the Advisory       Council should be extended, and in addition, identify whether       there are other committees, councils, or task forces that       have overlapping or similar duties to that of the Advisory       Council, and whether such committees, councils, or task       forces should be combined, including with respect to section       319E(a) of the Public Health Service Act (42 U.S.C. 247d-      5(a)).        TITLE VI--ADVANCING TECHNOLOGIES FOR MEDICAL COUNTERMEASURES       SEC. 601. ADMINISTRATION OF COUNTERMEASURES.         Section 319L(c)(4)(D)(iii) (42 U.S.C. 247d-      7e(c)(4)(D)(iii)) is amended by striking ``and platform       technologies'' and inserting ``platform technologies,       technologies to administer countermeasures, and technologies       to improve storage and transportation of countermeasures''.       SEC. 602. UPDATING DEFINITIONS OF OTHER TRANSACTIONS.         Section 319L (42 U.S.C. 247d-7e) is amended--        (1) in subsection (a)(3), by striking ``, such as'' and all       that follows through ``Code''; and        (2) in subsection (c)(5)(A)--        (A) in clause (i), by striking ``under this subsection''       and all that follows through ``Code'' and inserting ``(as       defined in subsection (a)(3)) under this subsection''; and        (B) in clause (ii)--        (i) by amending subclause (I) to read as follows:         ``(I) In general.--To the maximum extent practicable,       competitive procedures shall be used when entering into       transactions to carry out projects under this subsection.'';       and         (ii) in subclause (II)--         (I) by striking ``$20,000,000'' and inserting       ``$100,000,000'';        (II) by striking ``senior procurement executive for the       Department (as designated for purpose of section 16(c) of the       Office of Federal Procurement Policy Act (41 U.S.C.       414(c)))'' and inserting ``Assistant Secretary for Financial       Resources''; and        (III) by striking ``senior procurement executive under''       and inserting ``Assistant Secretary for Financial Resources       under''.       SEC. 603. MEDICAL COUNTERMEASURE MASTER FILES.         (a) In General.--The purpose of this section (including       section 565B of the Federal Food, Drug, and Cosmetic Act, as       added by subsection (b)) is to support and advance the       development or manufacture of security countermeasures,       qualified countermeasures, and qualified pandemic or epidemic       products by facilitating and encouraging submission of data       and information to support the development of such products,       and through clarifying the authority to cross-reference to       data and information previously submitted to the Secretary of       Health and Human Services (referred to in this section as the       ``Secretary''), including data and information submitted to       medical countermeasure master files or other master files.        (b) Medical Countermeasure Master Files.--Chapter V of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.)       is amended by inserting after section 565A the following:       ``SEC. 565B. MEDICAL COUNTERMEASURE MASTER FILES.         ``(a) Applicability of Reference.--        ``(1) In general.--A person may submit data and information       in a master file to the Secretary with the intent to       reference, or to authorize, in writing, another person to       reference, such data or information to support a medical       countermeasure submission (including a supplement or       amendment to any such submission), without requiring the       master file holder to disclose the data and information to       any such persons authorized to reference the master file.       Such data and information shall be available for reference by       the master file holder or by a person authorized by the       master file holder, in accordance with applicable privacy and       confidentiality protocols and regulations.        ``(2) Reference of certain master files.--In the case that       data or information within a medical countermeasure master       file is used only to support the conditional approval of an       application filed under section 571, such master file may be       relied upon to support the effectiveness of a product that is       the subject of a subsequent medical countermeasure submission       only if such application is supplemented by additional data       or information to support review and approval in a manner       consistent with the standards applicable to such review and       approval for such countermeasure, qualified countermeasure,       or qualified pandemic or epidemic product.        ``(b) Medical Countermeasure Master File Content.--        ``(1) In general.--A master file under this section may       include data or information to support--        ``(A) the development of medical countermeasure submissions       to support the approval, licensure, classification,       clearance, conditional approval, or authorization of one or       more security countermeasures, qualified countermeasures, or       qualified pandemic or epidemic products; and        ``(B) the manufacture of security countermeasures,       qualified countermeasures, or qualified pandemic or epidemic       products.        ``(2) Required updates.--The Secretary may require, as       appropriate, that the master file holder ensure that the       contents of such master file are updated during the time such       master file is referenced for a medical countermeasure       submission.        ``(c) Sponsor Reference.--        ``(1) In general.--Each incorporation of data or       information within a medical countermeasure master file shall       describe the incorporated material in a manner in which the       Secretary determines appropriate and that permits the review       of such information within such master file without       necessitating re-submission of such data or information.       Master files shall be submitted in an electronic format in       accordance with sections 512(b)(4), 571(a)(4), and 745A, as       applicable, and as specified in applicable guidance.        ``(2) Reference by a master file holder.--A master file       holder that is the sponsor of a medical countermeasure       submission shall notify the Secretary in writing of the       intent to reference the medical countermeasure master file as       a part of the submission.        ``(3) Reference by an authorized person.--A person       submitting an application for review may, where the Secretary       determines appropriate, incorporate by reference all or part       of the contents of a medical countermeasure master file, if       the master file holder authorizes the incorporation in       writing.        ``(d) Acknowledgment of and Reliance Upon a Master File by       the Secretary.--        ``(1) In general.--The Secretary shall provide the master       file holder with a written notification indicating that the       Secretary has reviewed and relied upon specified data or       information within a master file and the purposes for which       such data or information was incorporated by reference if the       Secretary has reviewed and relied upon such specified data or       information to support the approval,  [[Page H10380]]       classification, conditional approval, clearance, licensure,       or authorization of a security countermeasure, qualified       countermeasure, or qualified pandemic or epidemic product.       The Secretary may rely upon the data and information within       the medical countermeasure master file for which such written       notification was provided in additional applications, as       applicable and appropriate and upon the request of the master       file holder so notified in writing or by an authorized person       of such holder.        ``(2) Certain applications.--If the Secretary has reviewed       and relied upon specified data or information within a       medical countermeasure master file to support the conditional       approval of an application under section 571 to subsequently       support the approval, clearance, licensure, or authorization       of a security countermeasure, qualified countermeasure, or       qualified pandemic or epidemic product, the Secretary shall       provide a brief written description to the master file holder       regarding the elements of the application fulfilled by the       data or information within the master file and how such data       or information contained in such application meets the       standards of evidence under subsection (c) or (d) of section       505, subsection (d) of section 512, or section 351 of the       Public Health Service Act (as applicable), which shall not       include any trade secret or confidential commercial       information.        ``(e) Rules of Construction.--Nothing in this section shall       be construed to--        ``(1) limit the authority of the Secretary to approve,       license, clear, conditionally approve, or authorize drugs,       biological products, or devices pursuant to, as applicable,       this Act or section 351 of the Public Health Service Act (as       such applicable Act is in effect on the day before the date       of enactment of the Pandemic and All-Hazards Preparedness and       Advancing Innovation Act of 2018), including the standards of       evidence, and applicable conditions, for approval under the       applicable Act;        ``(2) alter the standards of evidence with respect to       approval, licensure, or clearance, as applicable, of drugs,       biological products, or devices under this Act or section 351       of the Public Health Service Act, including, as applicable,       the substantial evidence standards under sections 505(d) and       512(d) or this Act and section 351(a) of the Public Health       Service Act; or        ``(3) alter the authority of the Secretary under this Act       or the Public Health Service Act to determine the types of       data or information previously submitted by a sponsor or any       other person that may be incorporated by reference in an       application, request, or notification for a drug, biological       product, or device submitted under sections 505(i), 505(b),       505(j), 512(b)(1), 512(b)(2), 512(j), 564, 571, 520(g),       515(c), 513(f)(2), or 510(k) of this Act, or subsection (a)       or (k) of section 351 of the Public Health Service Act,       including a supplement or amendment to any such submission,       and the requirements associated with such reference.        ``(f) Definitions.--In this section:        ``(1) The term `master file holder' means a person who       submits data and information to the Secretary with the intent       to reference or authorize another person to reference such       data or information to support a medical countermeasure       submission, as described in subsection (a).        ``(2) The term `medical countermeasure submission' means an       investigational new drug application under section 505(i), a       new drug application under section 505(b), or an abbreviated       new drug application under section 505(j) of this Act, a       biological product license application under section 351(a)       of the Public Health Service Act or a biosimilar biological       product license application under section 351(k) of the       Public Health Service Act, a new animal drug application       under section 512(b)(1) or abbreviated new animal drug       application under section 512(b)(2), an application for       conditional approval of a new animal drug under section 571,       an investigational device application under section 520(g),       an application with respect to a device under section 515(c),       a request for classification of a device under section       513(f)(2), a notification with respect to a device under       section 510(k), or a request for an emergency use       authorization under section 564 to support--        ``(A) the approval, licensure, classification, clearance,       conditional approval, or authorization of a security       countermeasure, qualified countermeasure, or qualified       pandemic or epidemic product; or        ``(B) a new indication to an approved security       countermeasure, qualified countermeasure, or qualified       pandemic or epidemic product.        ``(3) The terms `qualified countermeasure', `security       countermeasure', and `qualified pandemic or epidemic product'       have the meanings given such terms in sections 319F-1, 319F-      2, and 319F-3, respectively, of the Public Health Service       Act.''.        (c) Stakeholder Input.--Not later than 18 months after the       date of enactment of this Act, the Secretary, acting through       the Commissioner of Food and Drugs and in consultation with       the Assistant Secretary for Preparedness and Response, shall       solicit input from stakeholders, including stakeholders       developing security countermeasures, qualified       countermeasures, or qualified pandemic or epidemic products,       and stakeholders developing technologies to assist in the       development of such countermeasures with respect to how the       Food and Drug Administration can advance the use of tools and       technologies to support and advance the development or       manufacture of security countermeasures, qualified       countermeasures, and qualified pandemic or epidemic products,       including through reliance on cross-referenced data and       information contained within master files and submissions       previously submitted to the Secretary as set forth in section       565B of the Federal Food, Drug, and Cosmetic Act, as added by       subsection (b).        (d) Guidance.--Not later than 2 years after the date of       enactment of this Act, the Secretary, acting through the       Commissioner of Food and Drugs, shall publish draft guidance       about how reliance on cross-referenced data and information       contained within master files under section 565B of the       Federal Food, Drug, and Cosmetic Act, as added by subsection       (b) or submissions otherwise submitted to the Secretary may       be used for specific tools or technologies (including       platform technologies) that have the potential to support and       advance the development or manufacture of security       countermeasures, qualified countermeasures, and qualified       pandemic or epidemic products. The Secretary, acting through       the Commissioner of Food and Drugs, shall publish the final       guidance not later than 3 years after the enactment of this       Act.       SEC. 604. ANIMAL RULE REPORT.         (a) Study.--The Comptroller General of the United States       shall conduct a study on the application of the requirements       under subsections (c) and (d) of section 565 of the of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb-4)       (referred to in this section as the ``animal rule'') as a       component of medical countermeasure advanced development       under the Biomedical Advanced Research and Development       Authority and regulatory review by the Food and Drug       Administration. In conducting such study, the Comptroller       General shall examine the following:        (1) The extent to which advanced development and review of       a medical countermeasure are coordinated between the       Biomedical Advanced Research and Development Authority and       the Food and Drug Administration, including activities that       facilitate appropriate and efficient design of studies to       support approval, licensure, and authorization under the       animal rule, consistent with the recommendations in the       animal rule guidance, issued pursuant to section 565(c) of       the Federal Food Drug and Cosmetic Act (21 U.S.C. 360bbb-      4(c)) and entitled ``Product Development Under the Animal       Rule: Guidance for Industry'' (issued in October 2015), to       resolve discrepancies in the design of adequate and well-      controlled efficacy studies conducted in animal models       related to the provision of substantial evidence of       effectiveness for the product approved, licensed, or       authorized under the animal rule.        (2) The consistency of the application of the animal rule       among and between review divisions within the Food and Drug       Administration.        (3) The flexibility pursuant to the animal rule to address       variations in countermeasure development and review       processes, including the extent to which qualified animal       models are adopted and used within the Food and Drug       Administration in regulatory decisionmaking with respect to       medical countermeasures.        (4) The extent to which the guidance issued under section       565(c) of the Federal Food Drug and Cosmetic Act (21 U.S.C.       360bbb-4(c)), entitled, ``Product Development Under the       Animal Rule: Guidance for Industry'' (issued in October       2015), has assisted in achieving the purposes described in       paragraphs (1), (2), and (3).        (b) Consultations.--In conducting the study under       subsection (a), the Comptroller General of the United States       shall consult with--        (1) the Federal agencies responsible for advancing,       reviewing, and procuring medical countermeasures, including       the Office of the Assistant Secretary for Preparedness and       Response, the Biomedical Advanced Research and Development       Authority, the Food and Drug Administration, and the       Department of Defense;        (2) manufacturers involved in the research and development       of medical countermeasures to address biological, chemical,       radiological, or nuclear threats; and        (3) other biodefense stakeholders, as applicable.        (c) Report.--Not later than 3 years after the date of       enactment of this Act, the Comptroller General of the United       States shall submit to the Committee on Health, Education,       Labor, and Pensions of the Senate and the Committee on Energy       and Commerce of the House of Representatives a report       containing the results of the study conducted under       subsection (a) and recommendations to improve the application       and consistency of the requirements under subsections (c) and       (d) of section 565 of the Federal Food, Drug and Cosmetic Act       (21 U.S.C. 360bbb-4) to support and expedite the research and       development of medical countermeasures, as applicable.        (d) Protection of National Security.--The Comptroller       General of the United States shall conduct the study and       issue the assessment and report under this section in a       manner that does not compromise national security.       SEC. 605. REVIEW OF THE BENEFITS OF GENOMIC ENGINEERING                     TECHNOLOGIES AND THEIR POTENTIAL ROLE IN                     NATIONAL SECURITY.         (a) Meeting.--  [[Page H10381]]         (1) In general.--Not later than 1 year after the date of       enactment of this Act, the Secretary of Health and Human       Services (referred to in this section as the ``Secretary'')       shall convene a meeting to discuss the potential role       advancements in genomic engineering technologies (including       genome editing technologies) may have in advancing national       health security. Such meeting shall be held in a manner that       does not compromise national security.        (2) Attendees.--The attendees of the meeting under       paragraph (1)--        (A) shall include--        (i) representatives from the Office of the Assistant       Secretary for Preparedness and Response, the National       Institutes of Health, the Centers for Disease Control and       Prevention, and the Food and Drug Administration; and        (ii) representatives from academic, private, and nonprofit       entities with expertise in genome engineering technologies,       biopharmaceuticals, medicine, or biodefense, and other       relevant stakeholders; and        (B) may include--        (i) other representatives from the Department of Health and       Human Services, as the Secretary determines appropriate; and        (ii) representatives from the Department of Homeland       Security, the Department of Defense, the Department of       Agriculture, and other departments, as the Secretary may       request for the meeting.        (3) Topics.--The meeting under paragraph (1) shall include       a discussion of--        (A) the current state of the science of genomic engineering       technologies related to national health security, including--        (i) medical countermeasure development, including potential       efficiencies in the development pathway and detection       technologies; and        (ii) the international and domestic regulation of products       utilizing genome editing technologies; and        (B) national security implications, including--        (i) capabilities of the United States to leverage genomic       engineering technologies as a part of the medical       countermeasure enterprise, including current applicable       research, development, and application efforts underway       within the Department of Defense;        (ii) the potential for state and non-state actors to       utilize genomic engineering technologies as a national health       security threat; and        (iii) security measures to monitor and assess the potential       threat that may result from utilization of genomic       engineering technologies and related technologies for the       purpose of compromising national health security.        (b) Report.--Not later than 270 days after the meeting       described in subsection (a) is held, the Assistant Secretary       for Preparedness and Response shall issue a report to the       congressional committees of jurisdiction on the topics       discussed at such meeting, and provide recommendations, as       applicable, to utilize innovations in genomic engineering       (including genome editing) and related technologies as a part       of preparedness and response activities to advance national       health security. Such report shall be issued in a manner that       does not compromise national security.       SEC. 606. REPORT ON VACCINES DEVELOPMENT.         Not later than one year after the date of the enactment of       this Act, the Secretary of Health and Human Services shall       submit to the Committee on Health, Education, Labor, and       Pensions of the Senate and the Committee on Energy and       Commerce of the House of Representatives a report describing       efforts and activities to coordinate with other countries and       international partners during recent public health       emergencies with respect to the research and advanced       research on, and development of, qualified pandemic or       epidemic products (as defined in section 319F-3 of the Public       Health Service Act (42 U.S.C. 247d-6d)). Such report may       include information regarding relevant work carried out under       section 319L(c)(5)(E) of the Public Health Service Act (42       U.S.C. 247d-7e(c)(5)(E)), through public-private       partnerships, and through collaborations with other countries       to assist with or expedite the research and development of       qualified pandemic or epidemic products. Such report shall       not include information that may compromise national       security.       SEC. 607. STRENGTHENING MOSQUITO ABATEMENT FOR SAFETY AND                     HEALTH.         (a) Reauthorization of Mosquito Abatement for Safety and       Health Program.--Section 317S (42 U.S.C. 247b-21) is       amended--        (1) in subsection (a)(1)(B)--        (A) by inserting ``including programs to address emerging       infectious mosquito-borne diseases,'' after ``subdivisions       for control programs,''; and        (B) by inserting ``or improving existing control programs''       before the period at the end;        (2) in subsection (b)--        (A) in paragraph (1), by inserting ``, including       improvement,'' after ``operation'';        (B) in paragraph (2)--        (i) in subparagraph (A)--         (I) in clause (ii), by striking ``or'' at the end;        (II) in clause (iii), by striking the semicolon at the end       and inserting ``, including an emerging infectious mosquito-      borne disease that presents a serious public health threat;       or''; and        (III) by adding at the end the following:         ``(iv) a public health emergency due to the incidence or       prevalence of a mosquito-borne disease that presents a       serious public health threat;''; and        (ii) by amending subparagraph (D) to read as follows:        ``(D)(i) is located in a State that has received a grant       under subsection (a); or        ``(ii) that demonstrates to the Secretary that the control       program is consistent with existing State mosquito control       plans or policies, or other applicable State preparedness       plans.'';        (C) in paragraph (4)(C), by striking ``that extraordinary''       and all that follows through the period at the end and       inserting the following: ``that--        ``(i) extraordinary economic conditions in the political       subdivision or consortium of political subdivisions involved       justify the waiver; or        ``(ii) the geographical area covered by a political       subdivision or consortium for a grant under paragraph (1) has       an extreme mosquito control need due to--         ``(I) the size or density of the potentially impacted human       population;        ``(II) the size or density of a mosquito population that       requires heightened control; or        ``(III) the severity of the mosquito-borne disease, such       that expected serious adverse health outcomes for the human       population justify the waiver.''; and         (D) by amending paragraph (6) to read as follows:        ``(6) Number of grants.--A political subdivision or a       consortium of political subdivisions may not receive more       than one grant under paragraph (1).''; and        (3) in subsection (f)--        (A) in paragraph (1) by striking ``for fiscal year 2003,       and such sums as may be necessary for each of fiscal years       2004 through 2007'' and inserting ``for each of fiscal years       2019 through 2023'';        (B) in paragraph (2), by striking ``the Public Health       Security and Bioterrorism Preparedness and Response Act of       2002'' and inserting ``this Act and other medical and public       health preparedness and response laws''; and        (C) in paragraph (3)--        (i) in the paragraph heading, by striking ``2004'' and       inserting ``2019''; and        (ii) by striking ``2004,'' and inserting ``2019,''.        (b) Epidemiology-Laboratory Capacity Grants.--Section 2821       (42 U.S.C. 300hh-31) is amended--        (1) in subsection (a)(1), by inserting ``, including       mosquito and other vector-borne diseases,'' after       ``infectious diseases''; and        (2) in subsection (b), by striking ``2010 through 2013''       and inserting ``2019 through 2023''.                    TITLE VII--MISCELLANEOUS PROVISIONS       SEC. 701. REAUTHORIZATIONS AND EXTENSIONS.         (a) Veterans Affairs.--Section 8117(g) of title 38, United       States Code, is amended by striking ``2014 through 2018'' and       inserting ``2019 through 2023''.        (b) Vaccine Tracking and Distribution.--Section 319A(e) (42       U.S.C. 247d-1(e)) is amended by striking ``2014 through       2018'' and inserting ``2019 through 2023''.        (c) Temporary Reassignment.--Section 319(e)(8) (42 U.S.C.       247d(e)(8)) is amended by striking ``2018'' and inserting       ``2023''.        (d) Strategic Innovation Partner.--Section       319L(c)(4)(E)(ix) (42 U.S.C. 247d-7e(c)(4)(E)(ix)) is amended       by striking ``2022'' and inserting ``2023''.        (e) Limited Antitrust Exemption.--        (1) In general.--Section 405 of the Pandemic and All-      Hazards Preparedness Act (Public Law 109-417; 42 U.S.C. 247d-      6a note) is amended--        (A) in subsection (a)(1)(A)--        (i) by striking ``Secretary of Health and Human Services       (referred to in this subsection as the `Secretary')'' and       inserting ``Secretary'';        (ii) by striking ``of the Public Health Service Act (42       U.S.C. 247d-6b)) (as amended by this Act'';        (iii) by striking ``of the Public Health Service Act (42       U.S.C. 247d-6a)) (as amended by this Act''; and        (iv) by striking ``of the Public Health Service Act (42       U.S.C. 247d-6d)'';        (B) in subsection (b), by striking ``12-year'' and       inserting ``17-year'';        (C) by redesignating such section 405 as section 319L-1;       and        (D) by transferring such section 319L-1, as redesignated,       to the Public Health Service Act (42 U.S.C. 201 et seq.), to       appear after section 319L of such Act (42 U.S.C. 247d-7e).        (2) Conforming amendment.--The table of contents in section       1(b) of the Pandemic and All-Hazards Preparedness Act (Public       Law 109-417) is amended by striking the item related to       section 405.        (f) Inapplicability of Certain Provisions.--Subsection       (e)(1) of section 319L (42 U.S.C. 247d-7e(e)(1)) is amended--        (1) by amending subparagraph (A) to read as follows:        ``(A) Non-disclosure of information.--        ``(i) In general.--Information described in clause (ii)       shall be deemed to be information described in section       552(b)(3) of title 5, United States Code.        ``(ii) Information described.--The information described in       this clause is information relevant to programs of the       Department of Health and Human Services that could compromise       national security and reveal significant and not otherwise       publicly known vulnerabilities of existing medical or public       health defenses against chemical, biological, radiological,       or nuclear threats, and is comprised of--  [[Page H10382]]         ``(I) specific technical data or scientific information       that is created or obtained during the countermeasure and       product advanced research and development carried out under       subsection (c);        ``(II) information pertaining to the location security,       personnel, and research materials and methods of high-      containment laboratories conducting research with select       agents, toxins, or other agents with a material threat       determination under section 319F-2(c)(2); or        ``(III) security and vulnerability assessments.'';         (2) by redesignating subparagraph (C) as subparagraph (D);        (3) by inserting after subparagraph (B) the following:        ``(C) Reporting.--One year after the date of enactment of       the Pandemic and All-Hazards Preparedness and Advancing       Innovation Act of 2018, and annually thereafter, the       Secretary shall report to the Committee on Health, Education,       Labor, and Pensions of the Senate and the Committee on Energy       and Commerce of the House of Representatives on the number of       instances in which the Secretary has used the authority under       this subsection to withhold information from disclosure, as       well as the nature of any request under section 552 of title       5, United States Code that was denied using such       authority.''; and        (4) in subparagraph (D), as so redesignated, by striking       ``12'' and inserting ``17''.       SEC. 702. LOCATION OF MATERIALS IN THE STOCKPILE.         Subsection (d) of section 319F-2 (42 U.S.C. 247d-6b) is       amended to read as follows:        ``(d) Disclosures.--No Federal agency may disclose under       section 552 of title 5, United States Code any information       identifying the location at which materials in the stockpile       described in subsection (a) are stored, or other information       regarding the contents or deployment capability of the       stockpile that could compromise national security.''.       SEC. 703. CYBERSECURITY.         (a) Strategy for Public Health Preparedness and Response to       Cybersecurity Threats.--        (1) Strategy.--Not later than 18 months after the date of       enactment of this Act, the Secretary of Health and Human       Services (referred to in this section as the ``Secretary'')       shall prepare and submit to the relevant committees of       Congress a strategy for public health preparedness and       response to address cybersecurity threats (as defined in       section 102 of Cybersecurity Information Sharing Act of 2015       (6 U.S.C. 1501)) that present a threat to national health       security. Such strategy shall include--        (A) identifying the duties, functions, and preparedness       goals for which the Secretary is responsible in order to       prepare for and respond to such cybersecurity threats,       including metrics by which to measure success in meeting       preparedness goals;        (B) identifying gaps in public health capabilities to       achieve such preparedness goals; and        (C) strategies to address identified gaps and strengthen       public health emergency preparedness and response       capabilities to address such cybersecurity threats.        (2) Protection of national security.--The Secretary shall       make such strategy available to the Committee on Health,       Education, Labor, and Pensions of the Senate, the Committee       on Energy and Commerce of the House of Representatives, and       other congressional committees of jurisdiction, in a manner       that does not compromise national security.        (b) Coordination of Preparedness for and Response to All-      hazards Public Health Emergencies.--Subparagraph (D) of       section 2811(b)(4) (42 U.S.C. 300hh-10(b)(4)) is amended to       read as follows:        ``(D) Policy coordination and strategic direction.--Provide       integrated policy coordination and strategic direction,       before, during, and following public health emergencies, with       respect to all matters related to Federal public health and       medical preparedness and execution and deployment of the       Federal response for public health emergencies and incidents       covered by the National Response Plan described in section       504(a)(6) of the Homeland Security Act of 2002 (6 U.S.C.       314(a)(6)), or any successor plan; and such Federal responses       covered by the National Cybersecurity Incident Response Plan       developed under section 228(c) of the Homeland Security Act       of 2002 (6 U.S.C. 149(c)), including public health       emergencies or incidents related to cybersecurity threats       that present a threat to national health security.''.       SEC. 704. STRATEGY AND REPORT.         Not later than 14 days after the date of the enactment of       this Act, the Secretary of Health and Human Services, in       coordination with the Assistant Secretary for Preparedness       and Response and the Assistant Secretary for the       Administration on Children and Families or other appropriate       office, and in collaboration with other departments, as       appropriate, shall submit to the Committee on Energy and       Commerce of the House of Representatives, the Committee on       Health, Education, Labor, and Pensions of the Senate, and       other relevant congressional committees--        (1) a formal strategy, including interdepartmental actions       and efforts to reunify children with their parents or       guardians, in all cases in which such children have been       separated from their parents or guardians as a result of the       initiative announced on April 6, 2018, and due to prosecution       under section 275(a) of the Immigration and Nationality Act       (8 U.S.C. 1325(a)), if the parent or guardian chooses such       reunification and the child--        (A) was separated from a parent or guardian and placed into       a facility funded by the Department of Health and Human       Services;        (B) as of the date of the enactment of this Act, remains in       the care of the Department of Health and Human Services; and        (C) can be safely reunited with such parent or guardian;       and        (2) a report on challenges and deficiencies related to the       oversight of, and care for, unaccompanied alien children and       appropriately reuniting such children with their parents or       guardians, and the actions taken to address any challenges       and deficiencies related to unaccompanied alien children in       the custody of the Department of Health and Human Services,       including deficiencies identified and publicly reported by       Congress, the Government Accountability Office, or the       Inspectors General of the Department of Health and Human       Services or other Federal departments.       SEC. 705. TECHNICAL AMENDMENTS.         (a) Public Health Service Act.--Title III (42 U.S.C. 241 et       seq.) is amended--        (1) in paragraphs (1) and (5) of section 319F-1(a) (42       U.S.C. 247d-6a(a)), by striking ``section 319F(h)'' each       place such term appears and inserting ``section 319F(e)'';       and        (2) in section 319K(a) (42 U.S.C. 247d-7d(a)), by striking       ``section 319F(h)(4)'' and inserting ``section 319F(e)(4)''.        (b) Public Health Security Grants.--Section 319C-1(b)(2)       (42 U.S.C. 247d-3a(b)(2)) is amended--        (1) in subparagraph (C), by striking ``individuals,,'' and       inserting ``individuals,''; and        (2) in subparagraph (F), by striking ``make satisfactory       annual improvement and describe'' and inserting ``makes       satisfactory annual improvement and describes''.        (c) Emergency Use Instructions.--Subparagraph (A) of       section 564A(e)(2) of the Federal Food, Drug, and Cosmetic       Act (21 U.S.C. 360bbb-3a(e)(2)) is amended by striking       ``subsection (a)(1)(C)(i)'' and inserting ``subsection       (a)(1)(C)''.        (d) Products Held for Emergency Use.--Section 564B(2) of       the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb-      3b) is amended--        (1) in subparagraph (B), by inserting a comma after       ``505''; and        (2) in subparagraph (C), by inserting ``or section 564A''       before the period at the end.        (e) Transparency.--Section 507(c)(3) of the Federal Food,       Drug, and Cosmetic Act (21 U.S.C. 357(c)(3)) is amended--        (1) by striking ``Nothing in'' and inserting the following:        ``(A) In general.--Nothing in'';        (2) by inserting ``or directing'' after ``authorizing'';        (3) by striking ``disclose any'' and inserting ``disclose--        ``(i) any'';        (4) by striking the period and inserting ``; or''; and        (5) by adding at the end the following:        ``(ii) in the case of a drug development tool that may be       used to support the development of a qualified       countermeasure, security countermeasure, or qualified       pandemic or epidemic product, as defined in sections 319F-1,       319F-2, and 319F-3, respectively, of the Public Health       Service Act, any information that the Secretary determines       has a significant potential to affect national security.        ``(B) Public acknowledgment.--In the case that the       Secretary, pursuant to subparagraph (A)(ii), does not make       information publicly available, the Secretary shall provide       on the internet website of the Food and Drug Administration       an acknowledgment of the information that has not been       disclosed, pursuant to subparagraph (A)(ii).''.   DIVISION B--OVER-THE-COUNTER MONOGRAPH SAFETY, INNOVATION, AND REFORM       SECTION 1000. SHORT TITLE; REFERENCES IN DIVISION.         (a) Short Title.--This division may be cited as the ``Over-      the-Counter Monograph Safety, Innovation, and Reform Act of       2018''.        (b) References.--Except as otherwise specified, any       reference to ``this Act'' contained in this division shall be       treated as referring only to the provisions of this division.                          TITLE I--OTC DRUG REVIEW       SEC. 1001. REGULATION OF CERTAIN NONPRESCRIPTION DRUGS THAT                     ARE MARKETED WITHOUT AN APPROVED DRUG                     APPLICATION.         (a) In General.--Chapter V of the Federal Food, Drug, and       Cosmetic Act is amended by inserting after section 505F of       such Act (21 U.S.C. 355g) the following:       ``SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION DRUGS THAT                     ARE MARKETED WITHOUT AN APPROVED DRUG                     APPLICATION.         ``(a) Nonprescription Drugs Marketed Without an Approved       Application.--Nonprescription drugs marketed without an       approved drug application under section 505, as of the date       of the enactment of this section, shall be treated in       accordance with this subsection.        ``(1) Drugs subject to a final monograph; category i drugs       subject to a tentative final monograph.--A drug is deemed to       be generally recognized as safe and effective under section       201(p)(1), not a new drug under section 201(p), and not       subject to section 503(b)(1), if--  [[Page H10383]]         ``(A) the drug is--        ``(i) in conformity with the requirements for       nonprescription use of a final monograph issued under part       330 of title 21, Code of Federal Regulations (except as       provided in paragraph (2)), the general requirements for       nonprescription drugs, and conditions or requirements under       subsections (b), (c), and (k); and        ``(ii) except as permitted by an order issued under       subsection (b) or, in the case of a minor change in the drug,       in conformity with an order issued under subsection (c), in a       dosage form that, immediately prior to the date of the       enactment of this section, has been used to a material extent       and for a material time under section 201(p)(2); or        ``(B) the drug is--        ``(i) classified in category I for safety and effectiveness       under a tentative final monograph that is the most recently       applicable proposal or determination issued under part 330 of       title 21, Code of Federal Regulations;        ``(ii) in conformity with the proposed requirements for       nonprescription use of such tentative final monograph, any       applicable subsequent determination by the Secretary, the       general requirements for nonprescription drugs, and       conditions or requirements under subsections (b), (c), and       (k); and        ``(iii) except as permitted by an order issued under       subsection (b) or, in the case of a minor change in the drug,       in conformity with an order issued under subsection (c), in a       dosage form that, immediately prior to the date of the       enactment of this section, has been used to a material extent       and for a material time under section 201(p)(2).        ``(2) Treatment of sunscreen drugs.--With respect to       sunscreen drugs subject to this section, the applicable       requirements in terms of conformity with a final monograph,       for purposes of paragraph (1)(A)(i), shall be the       requirements specified in part 352 of title 21, Code of       Federal Regulations, as published on May 21, 1999, beginning       on page 27687 of volume 64 of the Federal Register, except       that the applicable requirements governing effectiveness and       labeling shall be those specified in section 201.327 of title       21, Code of Federal Regulations.        ``(3) Category iii drugs subject to a tentative final       monograph; category i drugs subject to proposed monograph or       advance notice of proposed rulemaking.--A drug that is not       described in paragraph (1), (2), or (4) is not required to be       the subject of an application approved under section 505, and       is not subject to section 503(b)(1), if--        ``(A) the drug is--        ``(i) classified in category III for safety or       effectiveness in the preamble of a proposed rule establishing       a tentative final monograph that is the most recently       applicable proposal or determination for such drug issued       under part 330 of title 21, Code of Federal Regulations;        ``(ii) in conformity with--         ``(I) the conditions of use, including indication and       dosage strength, if any, described for such category III drug       in such preamble or in an applicable subsequent proposed       rule;        ``(II) the proposed requirements for drugs classified in       such tentative final monograph in category I in the most       recently proposed rule establishing requirements related to       such tentative final monograph and in any final rule       establishing requirements that are applicable to the drug;       and        ``(III) the general requirements for nonprescription drugs       and conditions or requirements under subsection (b) or (k);       and         ``(iii) in a dosage form that, immediately prior to the       date of the enactment of this section, had been used to a       material extent and for a material time under section       201(p)(2); or        ``(B) the drug is--        ``(i) classified in category I for safety and effectiveness       under a proposed monograph or advance notice of proposed       rulemaking that is the most recently applicable proposal or       determination for such drug issued under part 330 of title       21, Code of Federal Regulations;        ``(ii) in conformity with the requirements for       nonprescription use of such proposed monograph or advance       notice of proposed rulemaking, any applicable subsequent       determination by the Secretary, the general requirements for       nonprescription drugs, and conditions or requirements under       subsection (b) or (k); and        ``(iii) in a dosage form that, immediately prior to the       date of the enactment of this section, has been used to a       material extent and for a material time under section       201(p)(2).        ``(4) Category ii drugs deemed new drugs.--A drug that is       classified in category II for safety or effectiveness under a       tentative final monograph or that is subject to a       determination to be not generally recognized as safe and       effective in a proposed rule that is the most recently       applicable proposal issued under part 330 of title 21, Code       of Federal Regulations, shall be deemed to be a new drug       under section 201(p), misbranded under section 502(ee), and       subject to the requirement for an approved new drug       application under section 505 beginning on the day that is       180 calendar days after the date of the enactment of this       section, unless, before such day, the Secretary determines       that it is in the interest of public health to extend the       period during which the drug may be marketed without such an       approved new drug application.        ``(5) Drugs not grase deemed new drugs.--A drug that the       Secretary has determined not to be generally recognized as       safe and effective under section 201(p)(1) under a final       determination issued under part 330 of title 21, Code of       Federal Regulations, shall be deemed to be a new drug under       section 201(p), misbranded under section 502(ee), and subject       to the requirement for an approved new drug application under       section 505.        ``(6) Other drugs deemed new drugs.--Except as provided in       subsection (m), a drug is deemed to be a new drug under       section 201(p) and misbranded under section 502(ee) if the       drug--        ``(A) is not subject to section 503(b)(1); and        ``(B) is not described in paragraph (1), (2), (3), (4), or       (5), or subsection (b)(1)(B).        ``(b) Administrative Orders.--        ``(1) In general.--        ``(A) Determination.--The Secretary may, on the initiative       of the Secretary or at the request of one or more requestors,       issue an administrative order determining whether there are       conditions under which a specific drug, a class of drugs, or       a combination of drugs, is determined to be--        ``(i) not subject to section 503(b)(1); and        ``(ii) generally recognized as safe and effective under       section 201(p)(1).        ``(B) Effect.--A drug or combination of drugs shall be       deemed to not require approval under section 505 if such drug       or combination of drugs--        ``(i) is determined by the Secretary to meet the conditions       specified in clauses (i) and (ii) of subparagraph (A);        ``(ii) is marketed in conformity with an administrative       order under this subsection;        ``(iii) meets the general requirements for nonprescription       drugs; and        ``(iv) meets the requirements under subsections (c) and       (k).        ``(C) Standard.--The Secretary shall find that a drug is       not generally recognized as safe and effective under section       201(p)(1) if--        ``(i) the evidence shows that the drug is not generally       recognized as safe and effective under section 201(p)(1); or        ``(ii) the evidence is inadequate to show that the drug is       generally recognized as safe and effective under section       201(p)(1).        ``(2) Administrative orders initiated by the secretary.--        ``(A) In general.--In issuing an administrative order under       paragraph (1) upon the Secretary's initiative, the Secretary       shall--        ``(i) make reasonable efforts to notify informally, not       later than 2 business days before the issuance of the       proposed order, the sponsors of drugs who have a listing in       effect under section 510(j) for the drugs or combination of       drugs that will be subject to the administrative order;        ``(ii) after any such reasonable efforts of notification--         ``(I) issue a proposed administrative order by publishing       it on the website of the Food and Drug Administration and       include in such order the reasons for the issuance of such       order; and        ``(II) publish a notice of availability of such proposed       order in the Federal Register;         ``(iii) except as provided in subparagraph (B), provide for       a public comment period with respect to such proposed order       of not less than 45 calendar days; and        ``(iv) if, after completion of the proceedings specified in       clauses (i) through (iii), the Secretary determines that it       is appropriate to issue a final administrative order--         ``(I) issue the final administrative order, together with a       detailed statement of reasons, which order shall not take       effect until the time for requesting judicial review under       paragraph (3)(D)(ii) has expired;        ``(II) publish a notice of such final administrative order       in the Federal Register;        ``(III) afford requestors of drugs that will be subject to       such order the opportunity for formal dispute resolution up       to the level of the Director of the Center for Drug       Evaluation and Research, which initially must be requested       within 45 calendar days of the issuance of the order, and,       for subsequent levels of appeal, within 30 calendar days of       the prior decision; and        ``(IV) except with respect to drugs described in paragraph       (3)(B), upon completion of the formal dispute resolution       procedure, inform the persons which sought such dispute       resolution of their right to request a hearing.         ``(B) Exceptions.--When issuing an administrative order       under paragraph (1) on the Secretary's initiative proposing       to determine that a drug described in subsection (a)(3) is       not generally recognized as safe and effective under section       201(p)(1), the Secretary shall follow the procedures in       subparagraph (A), except that--        ``(i) the proposed order shall include notice of--         ``(I) the general categories of data the Secretary has       determined necessary to establish that the drug is generally       recognized as safe and effective under section 201(p)(1); and        ``(II) the format for submissions by interested persons;         ``(ii) the Secretary shall provide for a public comment       period of no less than 180 calendar days with respect to such       proposed order, except when the Secretary determines, for       good cause, that a shorter period is in the interest of       public health; and        ``(iii) any person who submits data in such comment period       shall include a certification that the person has submitted       all evidence created, obtained, or received by that person       that is both within the categories of data identified in the       proposed order and relevant to a determination as to whether       the drug is generally recognized as safe and effective under       section 201(p)(1).  [[Page H10384]]         ``(3) Hearings; judicial review.--        ``(A) In general.--Only a person who participated in each       stage of formal dispute resolution under subclause (III) of       paragraph (2)(A)(iv) of an administrative order with respect       to a drug may request a hearing concerning a final       administrative order issued under such paragraph with respect       to such drug. If a hearing is sought, such person must submit       a request for a hearing, which shall be based solely on       information in the administrative record, to the Secretary       not later than 30 calendar days after receiving notice of the       final decision of the formal dispute resolution procedure.        ``(B) No hearing required with respect to orders relating       to certain drugs.--        ``(i) In general.--The Secretary shall not be required to       provide notice and an opportunity for a hearing pursuant to       paragraph (2)(A)(iv) if the final administrative order       involved relates to a drug--         ``(I) that is described in subsection (a)(3)(A); and        ``(II) with respect to which no human or non-human data       studies relevant to the safety or effectiveness of such drug       have been submitted to the administrative record since the       issuance of the most recent tentative final monograph       relating to such drug.         ``(ii) Human data studies and non-human data defined.--In       this subparagraph:         ``(I) The term `human data studies' means clinical trials       of safety or effectiveness (including actual use studies),       pharmacokinetics studies, or bioavailability studies.        ``(II) The term `non-human data' means data from testing       other than with human subjects which provides information       concerning safety or effectiveness.         ``(C) Hearing procedures.--        ``(i) Denial of request for hearing.--If the Secretary       determines that information submitted in a request for a       hearing under subparagraph (A) with respect to a final       administrative order issued under paragraph (2)(A)(iv), does       not identify the existence of a genuine and substantial       question of material fact, the Secretary may deny such       request. In making such a determination, the Secretary may       consider only information and data that are based on relevant       and reliable scientific principles and methodologies.        ``(ii) Single hearing for multiple related requests.--If       more than one request for a hearing is submitted with respect       to the same administrative order under subparagraph (A), the       Secretary may direct that a single hearing be conducted in       which all persons whose hearing requests were granted may       participate.        ``(iii) Presiding officer.--The presiding officer of a       hearing requested under subparagraph (A) shall--         ``(I) be designated by the Secretary;        ``(II) not be an employee of the Center for Drug Evaluation       and Research; and        ``(III) not have been previously involved in the       development of the administrative order involved or       proceedings relating to that administrative order.         ``(iv) Rights of parties to hearing.--The parties to a       hearing requested under subparagraph (A) shall have the right       to present testimony, including testimony of expert       witnesses, and to cross-examine witnesses presented by other       parties. Where appropriate, the presiding officer may require       that cross-examination by parties representing substantially       the same interests be consolidated to promote efficiency and       avoid duplication.        ``(v) Final decision.--         ``(I) At the conclusion of a hearing requested under       subparagraph (A), the presiding officer of the hearing shall       issue a decision containing findings of fact and conclusions       of law. The decision of the presiding officer shall be final.        ``(II) The final decision may not take effect until the       period under subparagraph (D)(ii) for submitting a request       for judicial review of such decision expires.         ``(D) Judicial review of final administrative order.--        ``(i) In general.--The procedures described in section       505(h) shall apply with respect to judicial review of final       administrative orders issued under this subsection in the       same manner and to the same extent as such section applies to       an order described in such section except that the judicial       review shall be taken by filing in an appropriate district       court of the United States in lieu of the appellate courts       specified in such section.        ``(ii) Period to submit a request for judicial review.--A       person eligible to request a hearing under this paragraph and       seeking judicial review of a final administrative order       issued under this subsection shall file such request for       judicial review not later than 60 calendar days after the       latest of--         ``(I) the date on which notice of such order is published;        ``(II) the date on which a hearing with respect to such       order is denied under subparagraph (B) or (C)(i);        ``(III) the date on which a final decision is made       following a hearing under subparagraph (C)(v); or        ``(IV) if no hearing is requested, the date on which the       time for requesting a hearing expires.         ``(4) Expedited procedure with respect to administrative       orders initiated by the secretary.--        ``(A) Imminent hazard to the public health.--        ``(i) In general.--In the case of a determination by the       Secretary that a drug, class of drugs, or combination of       drugs subject to this section poses an imminent hazard to the       public health, the Secretary, after first making reasonable       efforts to notify, not later than 48 hours before issuance of       such order under this subparagraph, sponsors who have a       listing in effect under section 510(j) for such drug or       combination of drugs--         ``(I) may issue an interim final administrative order for       such drug, class of drugs, or combination of drugs under       paragraph (1), together with a detailed statement of the       reasons for such order;        ``(II) shall publish in the Federal Register a notice of       availability of any such order; and        ``(III) shall provide for a public comment period of at       least 45 calendar days with respect to such interim final       order.         ``(ii) Nondelegation.--The Secretary may not delegate the       authority to issue an interim final administrative order       under this subparagraph.        ``(B) Safety labeling changes.--        ``(i) In general.--In the case of a determination by the       Secretary that a change in the labeling of a drug, class of       drugs, or combination of drugs subject to this section is       reasonably expected to mitigate a significant or unreasonable       risk of a serious adverse event associated with use of the       drug, the Secretary may--         ``(I) make reasonable efforts to notify informally, not       later than 48 hours before the issuance of the interim final       order, the sponsors of drugs who have a listing in effect       under section 510(j) for such drug or combination of drugs;        ``(II) after reasonable efforts of notification, issue an       interim final administrative order in accordance with       paragraph (1) to require such change, together with a       detailed statement of the reasons for such order;        ``(III) publish in the Federal Register a notice of       availability of such order; and        ``(IV) provide for a public comment period of at least 45       calendar days with respect to such interim final order.         ``(ii) Content of order.--An interim final order issued       under this subparagraph with respect to the labeling of a       drug may provide for new warnings and other information       required for safe use of the drug.        ``(C) Effective date.--An order under subparagraph (A) or       (B) shall take effect on a date specified by the Secretary.        ``(D) Final order.--After the completion of the proceedings       in subparagraph (A) or (B), the Secretary shall--        ``(i) issue a final order in accordance with paragraph (1);        ``(ii) publish a notice of availability of such final       administrative order in the Federal Register; and        ``(iii) afford sponsors of such drugs that will be subject       to such an order the opportunity for formal dispute       resolution up to the level of the Director of the Center for       Drug Evaluation and Research, which must initially be within       45 calendar days of the issuance of the order, and for       subsequent levels of appeal, within 30 calendar days of the       prior decision.        ``(E) Hearings.--A sponsor of a drug subject to a final       order issued under subparagraph (D) and that participated in       each stage of formal dispute resolution under clause (iii) of       such subparagraph may request a hearing on such order. The       provisions of subparagraphs (A), (B), and (C) of paragraph       (3), other than paragraph (3)(C)(v)(II), shall apply with       respect to a hearing on such order in the same manner and to       the same extent as such provisions apply with respect to a       hearing on an administrative order issued under paragraph       (2)(A)(iv).        ``(F) Timing.--        ``(i) Final order and hearing.--The Secretary shall--         ``(I) not later than 6 months after the date on which the       comment period closes under subparagraph (A) or (B), issue a       final order in accordance with paragraph (1); and        ``(II) not later than 12 months after the date on which       such final order is issued, complete any hearing under       subparagraph (E).         ``(ii) Dispute resolution request.--The Secretary shall       specify in an interim final order issued under subparagraph       (A) or (B) such shorter periods for requesting dispute       resolution under subparagraph (D)(iii) as are necessary to       meet the requirements of this subparagraph.        ``(G) Judicial review.--A final order issued pursuant to       subparagraph (F) shall be subject to judicial review in       accordance with paragraph (3)(D).        ``(5) Administrative order initiated at the request of a       requestor.--        ``(A) In general.--In issuing an administrative order under       paragraph (1) at the request of a requestor with respect to       certain drugs, classes of drugs, or combinations of drugs--        ``(i) the Secretary shall, after receiving a request under       this subparagraph, determine whether the request is       sufficiently complete and formatted to permit a substantive       review;        ``(ii) if the Secretary determines that the request is       sufficiently complete and formatted to permit a substantive       review, the Secretary shall--         ``(I) file the request; and        ``(II) initiate proceedings with respect to issuing an       administrative order in accordance with paragraphs (2) and       (3); and         ``(iii) except as provided in paragraph (6), if the       Secretary determines that a request does not meet the       requirements for filing or is not sufficiently complete and       formatted to permit a substantive review, the requestor may  [[Page H10385]]       demand that the request be filed over protest, and the       Secretary shall initiate proceedings to review the request in       accordance with paragraph (2)(A).        ``(B) Request to initiate proceedings.--        ``(i) In general.--A requestor seeking an administrative       order under paragraph (1) with respect to certain drugs,       classes of drugs, or combinations of drugs, shall submit to       the Secretary a request to initiate proceedings for such       order in the form and manner as specified by the Secretary.       Such requestor may submit a request under this subparagraph       for the issuance of an administrative order--         ``(I) determining whether a drug is generally recognized as       safe and effective under section 201(p)(1), exempt from       section 503(b)(1), and not required to be the subject of an       approved application under section 505; or        ``(II) determining whether a change to a condition of use       of a drug is generally recognized as safe and effective under       section 201(p)(1), exempt from section 503(b)(1), and not       required to be the subject of an approved application under       section 505, if, absent such a changed condition of use, such       drug is--         ``(aa) generally recognized as safe and effective under       section 201(p)(1) in accordance with subsection (a)(1),       (a)(2), or an order under this subsection; or        ``(bb) subject to subsection (a)(3), but only if such       requestor initiates such request in conjunction with a       request for the Secretary to determine whether such drug is       generally recognized as safe and effective under section       201(p)(1), which is filed by the Secretary under subparagraph       (A)(ii).        ``(ii) Exception.--The Secretary is not required to       complete review of a request for a change described in clause       (i)(II) if the Secretary determines that there is an       inadequate basis to find the drug is generally recognized as       safe and effective under section 201(p)(1) under paragraph       (1) and issues a final order announcing that determination.        ``(iii) Withdrawal.--The requestor may withdraw a request       under this paragraph, according to the procedures set forth       pursuant to subsection (d)(2)(B). Notwithstanding any other       provision of this section, if such request is withdrawn, the       Secretary may cease proceedings under this subparagraph.        ``(C) Exclusivity.--        ``(i) In general.--A final administrative order issued in       response to a request under this section shall have the       effect of authorizing solely the order requestor (or the       licensees, assignees, or successors in interest of such       requestor with respect to the subject of such order), for a       period of 18 months following the effective date of such       final order and beginning on the date the requestor may       lawfully market such drugs pursuant to the order, to market       drugs--         ``(I) incorporating changes described in clause (ii); and        ``(II) subject to the limitations under clause (iv).         ``(ii) Changes described.--A change described in this       clause is a change subject to an order specified in clause       (i), which--         ``(I) provides for a drug to contain an active ingredient       (including any ester or salt of the active ingredient) not       previously incorporated in a drug described in clause (iii);       or        ``(II) provides for a change in the conditions of use of a       drug, for which new human data studies conducted or sponsored       by the requestor (or for which the requestor has an exclusive       right of reference) were essential to the issuance of such       order.         ``(iii) Drugs described.--The drugs described in this       clause are drugs--         ``(I) specified in subsection (a)(1), (a)(2), or (a)(3);        ``(II) subject to a final order issued under this section;        ``(III) subject to a final sunscreen order (as defined in       section 586(2)(A)); or        ``(IV) described in subsection (m)(1), other than drugs       subject to an active enforcement action under chapter III of       this Act.         ``(iv) Limitations on exclusivity.--         ``(I) In general.--Only one 18-month period under this       subparagraph shall be granted, under each order described in       clause (i), with respect to changes (to the drug subject to       such order) which are either--         ``(aa) changes described in clause (ii)(I), relating to       active ingredients; or        ``(bb) changes described in clause (ii)(II), relating to       conditions of use.         ``(II) No exclusivity allowed.--No exclusivity shall apply       to changes to a drug which are--         ``(aa) the subject of a Tier 2 OTC monograph order request       (as defined in section 744L);        ``(bb) safety-related changes, as defined by the Secretary,       or any other changes the Secretary considers necessary to       assure safe use; or        ``(cc) changes related to methods of testing safety or       efficacy.        ``(v) New human data studies defined.--In this       subparagraph, the term `new human data studies' means       clinical trials of safety or effectiveness (including actual       use studies), pharmacokinetics studies, or bioavailability       studies, the results of which--         ``(I) have not been relied on by the Secretary to support--         ``(aa) a proposed or final determination that a drug       described in subclause (I), (II), or (III) of clause (iii) is       generally recognized as safe and effective under section       201(p)(1); or        ``(bb) approval of a drug that was approved under section       505; and         ``(II) do not duplicate the results of another study that       was relied on by the Secretary to support--         ``(aa) a proposed or final determination that a drug       described in subclause (I), (II), or (III) of clause (iii) is       generally recognized as safe and effective under section       201(p)(1); or        ``(bb) approval of a drug that was approved under section       505.        ``(6) Information regarding safe nonprescription marketing       and use as condition for filing a generally recognized as       safe and effective request.--        ``(A) In general.--In response to a request under this       section that a drug described in subparagraph (B) be       generally recognized as safe and effective, the Secretary--        ``(i) may file such request, if the request includes       information specified under subparagraph (C) with respect to       safe nonprescription marketing and use of such drug; or        ``(ii) if the request fails to include information       specified under subparagraph (C), shall refuse to file such       request and require that nonprescription marketing of the       drug be pursuant to a new drug application as described in       subparagraph (D).        ``(B) Drug described.--A drug described in this       subparagraph is a nonprescription drug which contains an       active ingredient not previously incorporated in a drug--        ``(i) specified in subsection (a)(1), (a)(2), or (a)(3);        ``(ii) subject to a final order under this section; or        ``(iii) subject to a final sunscreen order (as defined in       section 586(2)(A)).        ``(C) Information demonstrating prima facie safe       nonprescription marketing and use.--Information specified in       this subparagraph, with respect to a request described in       subparagraph (A)(i), is--        ``(i) information sufficient for a prima facie       demonstration that the drug subject to such request has a       verifiable history of being marketed and safely used by       consumers in the United States as a nonprescription drug       under comparable conditions of use;        ``(ii) if the drug has not been previously marketed in the       United States as a nonprescription drug, information       sufficient for a prima facie demonstration that the drug was       marketed and safely used under comparable conditions of       marketing and use in a country listed in section 802(b)(1)(A)       or designated by the Secretary in accordance with section       802(b)(1)(B)--         ``(I) for such period as needed to provide reasonable       assurances concerning the safe nonprescription use of the       drug; and        ``(II) during such time was subject to sufficient       monitoring by a regulatory body considered acceptable by the       Secretary for such monitoring purposes, including for adverse       events associated with nonprescription use of the drug; or         ``(iii) if the Secretary determines that information       described in clause (i) or (ii) is not needed to provide a       prima facie demonstration that the drug can be safely       marketed and used as a nonprescription drug, such other       information the Secretary determines is sufficient for such       purposes.        ``(D) Marketing pursuant to new drug application.--In the       case of a request described in subparagraph (A)(ii), the drug       subject to such request may be re-submitted for filing only       if--        ``(i) the drug is marketed as a nonprescription drug, under       conditions of use comparable to the conditions specified in       the request, for such period as the Secretary determines       appropriate (not to exceed 5 consecutive years) pursuant to       an application approved under section 505; and        ``(ii) during such period, 1,000,000 retail packages of the       drug, or an equivalent quantity as determined by the       Secretary, were distributed for retail sale, as determined in       such manner as the Secretary finds appropriate.        ``(E) Rule of application.--Except in the case of a request       involving a drug described in section 586(9), as in effect on       January 1, 2017, if the Secretary refuses to file a request       under this paragraph, the requestor may not file such request       over protest under paragraph (5)(A)(iii).        ``(7) Packaging.--An administrative order issued under       paragraph (2), (4)(A), or (5) may include requirements for       the packaging of a drug to encourage use in accordance with       labeling. Such requirements may include unit dose packaging,       requirements for products intended for use by pediatric       populations, requirements to reduce risk of harm from       unsupervised ingestion, and other appropriate requirements.       This paragraph does not authorize the Food and Drug       Administration to require standards or testing procedures as       described in part 1700 of title 16, Code of Federal       Regulations.        ``(8) Final and tentative final monographs for category i       drugs deemed final administrative orders.--        ``(A) In general.--A final monograph or tentative final       monograph described in subparagraph (B) shall be deemed to be       a final administrative order under this subsection and may be       amended, revoked, or otherwise modified in accordance with       the procedures of this subsection.        ``(B) Monographs described.--For purposes of subparagraph       (A), a final monograph or tentative final monograph is       described in this subparagraph if it--        ``(i) establishes conditions of use for a drug described in       paragraph (1) or (2) of subsection (a); and        ``(ii) represents the most recently promulgated version of       such conditions, including  [[Page H10386]]       as modified, in whole or in part, by any proposed or final       rule.        ``(C) Deemed orders include harmonizing technical       amendments.--The deemed establishment of a final       administrative order under subparagraph (A) shall be       construed to include any technical amendments to such order       as the Secretary determines necessary to ensure that such       order is appropriately harmonized, in terms of terminology or       cross-references, with the applicable provisions of this Act       (and regulations thereunder) and any other orders issued       under this section.        ``(c) Procedure for Minor Changes.--        ``(1) In general.--Minor changes in the dosage form of a       drug that is described in paragraph (1) or (2) of subsection       (a) or the subject of an order issued under subsection (b)       may be made by a requestor without the issuance of an order       under subsection (b) if--        ``(A) the requestor maintains such information as is       necessary to demonstrate that the change--        ``(i) will not affect the safety or effectiveness of the       drug; and        ``(ii) will not materially affect the extent of absorption       or other exposure to the active ingredient in comparison to a       suitable reference product; and        ``(B) the change is in conformity with the requirements of       an applicable administrative order issued by the Secretary       under paragraph (3).        ``(2) Additional information.--        ``(A) Access to records.--A sponsor shall submit records       requested by the Secretary relating to such a minor change       under section 704(a)(4), within 15 business days of receiving       such a request, or such longer period as the Secretary may       provide.        ``(B) Insufficient information.--If the Secretary       determines that the information contained in such records is       not sufficient to demonstrate that the change does not affect       the safety or effectiveness of the drug or materially affect       the extent of absorption or other exposure to the active       ingredient, the Secretary--        ``(i) may so inform the sponsor of the drug in writing; and        ``(ii) if the Secretary so informs the sponsor, shall       provide the sponsor of the drug with a reasonable opportunity       to provide additional information.        ``(C) Failure to submit sufficient information.--If the       sponsor fails to provide such additional information within a       time prescribed by the Secretary, or if the Secretary       determines that such additional information does not       demonstrate that the change does not--        ``(i) affect the safety or effectiveness of the drug; or        ``(ii) materially affect the extent of absorption or other       exposure to the active ingredient in comparison to a suitable       reference product,       the drug as modified is a new drug under section 201(p) and       shall be deemed to be misbranded under section 502(ee).        ``(3) Determining whether a change will affect safety or       effectiveness.--        ``(A) In general.--The Secretary shall issue one or more       administrative orders specifying requirements for determining       whether a minor change made by a sponsor pursuant to this       subsection will affect the safety or effectiveness of a drug       or materially affect the extent of absorption or other       exposure to an active ingredient in the drug in comparison to       a suitable reference product, together with guidance for       applying those orders to specific dosage forms.        ``(B) Standard practices.--The orders and guidance issued       by the Secretary under subparagraph (A) shall take into       account relevant public standards and standard practices for       evaluating the quality of drugs, and may take into account       the special needs of populations, including children.        ``(d) Confidentiality of Information Submitted to the       Secretary.--        ``(1) In general.--Subject to paragraph (2), any       information, including reports of testing conducted on the       drug or drugs involved, that is submitted by a requestor in       connection with proceedings on an order under this section       (including any minor change under subsection (c)) and is a       trade secret or confidential information subject to section       552(b)(4) of title 5, United States Code, or section 1905 of       title 18, United States Code, shall not be disclosed to the       public unless the requestor consents to that disclosure.        ``(2) Public availability.--        ``(A) In general.--Except as provided in subparagraph (B),       the Secretary shall--        ``(i) make any information submitted by a requestor in       support of a request under subsection (b)(5)(A) available to       the public not later than the date on which the proposed       order is issued; and        ``(ii) make any information submitted by any other person       with respect to an order requested (or initiated by the       Secretary) under subsection (b), available to the public upon       such submission.        ``(B) Limitations on public availability.--Information       described in subparagraph (A) shall not be made public if--        ``(i) the information pertains to pharmaceutical quality       information, unless such information is necessary to       establish standards under which a drug is generally       recognized as safe and effective under section 201(p)(1);        ``(ii) the information is submitted in a requestor-      initiated request, but the requestor withdraws such request,       in accordance with withdrawal procedures established by the       Secretary, before the Secretary issues the proposed order;        ``(iii) the Secretary requests and obtains the information       under subsection (c) and such information is not submitted in       relation to an order under subsection (b); or        ``(iv) the information is of the type contained in raw       datasets.        ``(e) Updates to Drug Listing Information.--A sponsor who       makes a change to a drug subject to this section shall submit       updated drug listing information for the drug in accordance       with section 510(j) within 30 calendar days of the date when       the drug is first commercially marketed, except that a       sponsor who was the order requestor with respect to an order       subject to subsection (b)(5)(C) (or a licensee, assignee, or       successor in interest of such requestor) shall submit updated       drug listing information on or before the date when the drug       is first commercially marketed.        ``(f) Approvals Under Section 505.--The provisions of this       section shall not be construed to preclude a person from       seeking or maintaining the approval of an application for a       drug under sections 505(b)(1), 505(b)(2), and 505(j). A       determination under this section that a drug is not subject       to section 503(b)(1), is generally recognized as safe and       effective under section 201(p)(1), and is not a new drug       under section 201(p) shall constitute a finding that the drug       is safe and effective that may be relied upon for purposes of       an application under section 505(b)(2), so that the applicant       shall be required to submit for purposes of such application       only information needed to support any modification of the       drug that is not covered by such determination under this       section.        ``(g) Public Availability of Administrative Orders.--The       Secretary shall establish, maintain, update (as determined       necessary by the Secretary but no less frequently than       annually), and make publicly available, with respect to       orders issued under this section--        ``(1) a repository of each final order and interim final       order in effect, including the complete text of the order;       and        ``(2) a listing of all orders proposed and under       development under subsection (b)(2), including--        ``(A) a brief description of each such order; and        ``(B) the Secretary's expectations, if resources permit,       for issuance of proposed orders over a 3-year period.        ``(h) Development Advice to Sponsors or Requestors.--The       Secretary shall establish procedures under which sponsors or       requestors may meet with appropriate officials of the Food       and Drug Administration to obtain advice on the studies and       other information necessary to support submissions under this       section and other matters relevant to the regulation of       nonprescription drugs and the development of new       nonprescription drugs under this section.        ``(i) Participation of Multiple Sponsors or Requestors.--      The Secretary shall establish procedures to facilitate       efficient participation by multiple sponsors or requestors in       proceedings under this section, including provision for joint       meetings with multiple sponsors or requestors or with       organizations nominated by sponsors or requestors to       represent their interests in a proceeding.        ``(j) Electronic Format.--All submissions under this       section shall be in electronic format.        ``(k) Effect on Existing Regulations Governing       Nonprescription Drugs.--        ``(1) Regulations of general applicability to       nonprescription drugs.--Except as provided in this       subsection, nothing in this section supersedes regulations       establishing general requirements for nonprescription drugs,       including regulations of general applicability contained in       parts 201, 250, and 330 of title 21, Code of Federal       Regulations, or any successor regulations. The Secretary       shall establish or modify such regulations by means of       rulemaking in accordance with section 553 of title 5, United       States Code.        ``(2) Regulations establishing requirements for specific       nonprescription drugs.--        ``(A) The provisions of section 310.545 of title 21, Code       of Federal Regulations, as in effect on the day before the       date of the enactment of this section, shall be deemed to be       a final order under subsection (b).        ``(B) Regulations in effect on the day before the date of       the enactment of this section, establishing requirements for       specific nonprescription drugs marketed pursuant to this       section (including such requirements in parts 201 and 250 of       title 21, Code of Federal Regulations), shall be deemed to be       final orders under subsection (b), only as they apply to       drugs--        ``(i) subject to paragraph (1), (2), (3), or (4) of       subsection (a); or        ``(ii) otherwise subject to an order under this section.        ``(3) Withdrawal of regulations.--The Secretary shall       withdraw regulations establishing final monographs and the       procedures governing the over-the-counter drug review under       part 330 and other relevant parts of title 21, Code of       Federal Regulations (as in effect on the day before the date       of the enactment of this section), or make technical changes       to such regulations to ensure conformity with appropriate       terminology and cross references. Notwithstanding subchapter       II of chapter 5 of title 5, United States Code, any such       withdrawal or technical changes shall be made without public       notice and comment and shall be effective upon publication       through notice in the Federal Register (or upon such date as       specified in such notice).  [[Page H10387]]         ``(l) Guidance.--The Secretary shall issue guidance that       specifies--        ``(1) the procedures and principles for formal meetings       between the Secretary and sponsors or requestors for drugs       subject to this section;        ``(2) the format and content of data submissions to the       Secretary under this section;        ``(3) the format of electronic submissions to the Secretary       under this section;        ``(4) consolidated proceedings for appeal and the       procedures for such proceedings where appropriate; and        ``(5) for minor changes in drugs, recommendations on how to       comply with the requirements in orders issued under       subsection (c)(3).        ``(m) Rule of Construction.--        ``(1) In general.--This section shall not affect the       treatment or status of a nonprescription drug--        ``(A) that is marketed without an application approved       under section 505 as of the date of the enactment of this       section;        ``(B) that is not subject to an order issued under this       section; and        ``(C) to which paragraphs (1), (2), (3), (4), or (5) of       subsection (a) do not apply.        ``(2) Treatment of products previously found to be subject       to time and extent requirements.--        ``(A) Notwithstanding subsection (a), a drug described in       subparagraph (B) may only be lawfully marketed, without an       application approved under section 505, pursuant to an order       issued under this section.        ``(B) A drug described in this subparagraph is a drug       which, prior to the date of the enactment of this section,       the Secretary determined in a proposed or final rule to be       ineligible for review under the OTC drug review (as such       phrase `OTC drug review' was used in section 330.14 of title       21, Code of Federal Regulations, as in effect on the day       before the date of the enactment of this section).        ``(3) Preservation of authority.--        ``(A) Nothing in paragraph (1) shall be construed to       preclude or limit the applicability of any provision of this       Act other than this section.        ``(B) Nothing in subsection (a) shall be construed to       prohibit the Secretary from issuing an order under this       section finding a drug to be not generally recognized as safe       and effective under section 201(p)(1), as the Secretary       determines appropriate.        ``(n) Investigational New Drugs.--A drug is not subject to       this section if an exemption for investigational use under       section 505(i) is in effect for such drug.        ``(o) Inapplicability of Paperwork Reduction Act.--Chapter       35 of title 44, United States Code, shall not apply to       collections of information made under this section.        ``(p) Inapplicability of Notice and Comment Rulemaking and       Other Requirements.--The requirements of subsection (b) shall       apply with respect to orders issued under this section       instead of the requirements of subchapter II of chapter 5 of       title 5, United States Code.        ``(q) Definitions.--In this section:        ``(1) The term `nonprescription drug' refers to a drug not       subject to the requirements of section 503(b)(1).        ``(2) The term `sponsor' refers to any person marketing,       manufacturing, or processing a drug that--        ``(A) is listed pursuant to section 510(j); and        ``(B) is or will be subject to an administrative order       under this section of the Food and Drug Administration.        ``(3) The term `requestor' refers to any person or group of       persons marketing, manufacturing, processing, or developing a       drug.''.        (b) GAO Study.--Not later than 4 years after the date of       enactment of this Act, the Comptroller General of the United       States shall submit a study to the Committee on Energy and       Commerce of the House of Representatives and the Committee on       Health, Education, Labor, and Pensions of the Senate       addressing the effectiveness and overall impact of       exclusivity under section 505G of the Federal Food, Drug, and       Cosmetic Act, as added by subsection (a), and section 586C of       such Act (21 U.S.C. 360fff-3), including the impact of such       exclusivity on consumer access. Such study shall include--        (1) an analysis of the impact of exclusivity under such       section 505G for nonprescription drug products, including--        (A) the number of nonprescription drug products that were       granted exclusivity and the indication for which the       nonprescription drug products were determined to be generally       recognized as safe and effective;        (B) whether the exclusivity for such drug products was       granted for--        (i) a new active ingredient (including any ester or salt of       the active ingredient); or        (ii) changes in the conditions of use of a drug, for which       new human data studies conducted or sponsored by the       requestor were essential;        (C) whether, and to what extent, the exclusivity impacted       the requestor's or sponsor's decision to develop the drug       product;        (D) an analysis of the implementation of the exclusivity       provision in such section 505G, including--        (i) the resources used by the Food and Drug Administration;        (ii) the impact of such provision on innovation, as well as       research and development in the nonprescription drug market;        (iii) the impact of such provision on competition in the       nonprescription drug market;        (iv) the impact of such provision on consumer access to       nonprescription drug products;        (v) the impact of such provision on the prices of       nonprescription drug products; and        (vi) whether the administrative orders initiated by       requestors under such section 505G have been sufficient to       encourage the development of nonprescription drug products       that would likely not be otherwise developed, or developed in       as timely a manner; and        (E) whether the administrative orders initiated by       requestors under such section 505G have been sufficient       incentive to encourage innovation in the nonprescription drug       market; and        (2) an analysis of the impact of exclusivity under such       section 586C for sunscreen ingredients, including--        (A) the number of sunscreen ingredients that were granted       exclusivity and the specific ingredient that was determined       to be generally recognized as safe and effective;        (B) whether, and to what extent, the exclusivity impacted       the requestor's or sponsor's decision to develop the       sunscreen ingredient;        (C) whether, and to what extent, the sunscreen ingredient       granted exclusivity had previously been available outside of       the United States;        (D) an analysis of the implementation of the exclusivity       provision in such section 586C, including--        (i) the resources used by the Food and Drug Administration;        (ii) the impact of such provision on innovation, as well as       research and development in the sunscreen market;        (iii) the impact of such provision on competition in the       sunscreen market;        (iv) the impact of such provision on consumer access to       sunscreen products;        (v) the impact of such provision on the prices of sunscreen       products; and        (vi) whether the administrative orders initiated by       requestors under such section 505G have been utilized by       sunscreen ingredient sponsors and whether such process has       been sufficient to encourage the development of sunscreen       ingredients that would likely not be otherwise developed, or       developed in as timely a manner; and        (E) whether the administrative orders initiated by       requestors under such section 586C have been sufficient       incentive to encourage innovation in the sunscreen market.        (c) Conforming Amendment.--Section 751(d)(1) of the Federal       Food, Drug, and Cosmetic Act (21 U.S.C. 379r(d)(1)) is       amended--        (1) in the matter preceding subparagraph (A)--        (A) by striking ``final regulation promulgated'' and       inserting ``final order under section 505G''; and        (B) by striking ``and not misbranded''; and        (2) in subparagraph (A), by striking ``regulation in       effect'' and inserting ``regulation or order in effect''.       SEC. 1002. MISBRANDING.         Section 502 of the Federal Food, Drug, and Cosmetic Act (21       U.S.C. 352) is amended by adding at the end the following:        ``(ee) If it is a nonprescription drug that is subject to       section 505G, is not the subject of an application approved       under section 505, and does not comply with the requirements       under section 505G.        ``(ff) If it is a drug and it was manufactured, prepared,       propagated, compounded, or processed in a facility for which       fees have not been paid as required by section 744M.''.       SEC. 1003. DRUGS EXCLUDED FROM THE OVER-THE-COUNTER DRUG                     REVIEW.         (a) In General.--Nothing in this Act (or the amendments       made by this Act) shall apply to any nonprescription drug (as       defined in section 505G(q) of the Federal Food, Drug, and       Cosmetic Act, as added by section 1001 of this Act) which was       excluded by the Food and Drug Administration from the Over-      the-Counter Drug Review in accordance with the paragraph       numbered 25 on page 9466 of volume 37 of the Federal       Register, published on May 11, 1972.        (b) Rule of Construction.--Nothing in this section shall be       construed to preclude or limit the applicability of any other       provision of the Federal Food, Drug, and Cosmetic Act (21       U.S.C. 301 et seq.).       SEC. 1004. TREATMENT OF SUNSCREEN INNOVATION ACT.         (a) Review of Nonprescription Sunscreen Active       Ingredients.--        (1) Applicability of section 505g for pending       submissions.--        (A) In general.--A sponsor of a nonprescription sunscreen       active ingredient or combination of nonprescription sunscreen       active ingredients that, as of the date of enactment of this       Act, is subject to a proposed sunscreen order under section       586C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.       360fff-3) may elect, by means of giving written notification       to the Secretary of Health and Human Services within 180       calendar days of the enactment of this Act, to transition       into the review of such ingredient or combination of       ingredients pursuant to the process set out in section 505G       of the Federal Food, Drug, and Cosmetic Act, as added by       section 1001 of this Act.        (B) Election exercised.--Upon receipt by the Secretary of       Health and Human Services of a timely notification under       subparagraph (A)--        (i) the proposed sunscreen order involved is deemed to be a       request for an order under subsection (b) of section 505G of       the Federal Food, Drug, and Cosmetic Act, as added by section       1001 of this Act; and        (ii) such order is deemed to have been accepted for filing       under subsection (b)(6)(A)(i) of such section 505G.  [[Page H10388]]         (C) Election not exercised.--If a notification under       subparagraph (A) is not received by the Secretary of Health       and Human Services within 180 calendar days of the date of       enactment of this Act, the review of the proposed sunscreen       order described in subparagraph (A)--        (i) shall continue under section 586C of the Federal Food,       Drug, and Cosmetic Act (21 U.S.C. 360fff-3); and        (ii) shall not be eligible for review under section 505G,       added by section 1001 of this Act.        (2) Definitions.--In this subsection, the terms       ``sponsor'', ``nonprescription'', ``sunscreen active       ingredient'', and ``proposed sunscreen order'' have the       meanings given to those terms in section 586 of the Federal       Food, Drug, and Cosmetic Act (21 U.S.C. 360fff).        (b) Amendments to Sunscreen Provisions.--        (1) Final sunscreen orders.--Paragraph (3) of section       586C(e) of the Federal Food, Drug, and Cosmetic Act (21       U.S.C. 360fff-3(e)) is amended to read as follows:        ``(3) Relationship to orders under section 505g.--A final       sunscreen order shall be deemed to be a final order under       section 505G.''.        (2) Meetings.--Paragraph (7) of section 586C(b) of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff-3(b))       is amended--        (A) by striking ``A sponsor may request'' and inserting the       following:        ``(A) In general.--A sponsor may request''; and        (B) by adding at the end the following:        ``(B) Confidential meetings.--A sponsor may request one or       more confidential meetings with respect to a proposed       sunscreen order, including a letter deemed to be a proposed       sunscreen order under paragraph (3), to discuss matters       relating to data requirements to support a general       recognition of safety and effectiveness involving       confidential information and public information related to       such proposed sunscreen order, as appropriate. The Secretary       shall convene a confidential meeting with such sponsor in a       reasonable time period. If a sponsor requests more than one       confidential meeting for the same proposed sunscreen order,       the Secretary may refuse to grant an additional confidential       meeting request if the Secretary determines that such       additional confidential meeting is not reasonably necessary       for the sponsor to advance its proposed sunscreen order, or       if the request for a confidential meeting fails to include       sufficient information upon which to base a substantive       discussion. The Secretary shall publish a post-meeting       summary of each confidential meeting under this subparagraph       that does not disclose confidential commercial information or       trade secrets. This subparagraph does not authorize the       disclosure of confidential commercial information or trade       secrets subject to 552(b)(4) of title 5, United States Code,       or section 1905 of title 18, United States Code.''.        (3) Exclusivity.--Section 586C of the Federal Food, Drug,       and Cosmetic Act (21 U.S.C. 360fff-3) is amended by adding at       the end the following:        ``(f) Exclusivity.--        ``(1) In general.--A final sunscreen order shall have the       effect of authorizing solely the order requestor (or the       licensees, assignees, or successors in interest of such       requestor with respect to the subject of such request and       listed under paragraph (5)) for a period of 18 months, to       market a sunscreen ingredient under this section       incorporating changes described in paragraph (2) subject to       the limitations under paragraph (4), beginning on the date       the requestor (or any licensees, assignees, or successors in       interest of such requestor with respect to the subject of       such request and listed under paragraph (5)) may lawfully       market such sunscreen ingredient pursuant to the order.        ``(2) Changes described.--A change described in this       paragraph is a change subject to an order specified in       paragraph (1) that permits a sunscreen to contain an active       sunscreen ingredient not previously incorporated in a       marketed sunscreen listed in paragraph (3).        ``(3) Marketed sunscreen.--The marketed sunscreen       ingredients described in this paragraph are sunscreen       ingredients--        ``(A) marketed in accordance with a final monograph for       sunscreen drug products set forth at part 352 of title 21,       Code of Federal Regulations (as published at 64 Fed. Reg.       27687); or        ``(B) marketed in accordance with a final order issued       under this section.        ``(4) Limitations on exclusivity.--Only one 18-month period       may be granted per ingredient under paragraph (1).        ``(5) Listing of licensees, assignees, or successors in       interest.--Requestors shall submit to the Secretary at the       time when a drug subject to such request is introduced or       delivered for introduction into interstate commerce, a list       of licensees, assignees, or successors in interest under       paragraph (1).''.        (4) Sunset provision.--Subchapter I of chapter V of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360fff et       seq.) is amended by adding at the end the following:       ``SEC. 586H. SUNSET.         ``This subchapter shall cease to be effective at the end of       fiscal year 2022.''.        (5) Treatment of final sunscreen order.--The Federal Food,       Drug, and Cosmetic Act is amended by striking section 586E of       such Act (21 U.S.C. 360fff-5).        (c) Treatment of Authority Regarding Finalization of       Sunscreen Monograph.--        (1) In general.--        (A) Revision of final sunscreen order.--Not later than       November 26, 2019, the Secretary of Health and Human Services       (referred to in this subsection as the ``Secretary'') shall       amend and revise the final administrative order concerning       nonprescription sunscreen (referred to in this subsection as       the ``sunscreen order'') for which the content, prior to the       date of enactment of this Act, was represented by the final       monograph for sunscreen drug products set forth in part 352       of title 21, Code of Federal Regulations (as in effect on May       21, 1999).        (B) Issuance of revised sunscreen order; effective date.--A       revised sunscreen order described in subparagraph (A) shall       be--        (i) issued in accordance with the procedures described in       section 505G(c)(2) of the Federal Food, Drug, and Cosmetic       Act;        (ii) issued in proposed form not later than May 28, 2019;        (iii) effective not later than November 26, 2020; and        (iv) issued by the Secretary at least 1 year prior to the       effective date of the revised order.        (2) Reports.--If a revised sunscreen order issued under       paragraph (1) does not include provisions related to the       effectiveness of various sun protection factor levels, and       does not address all dosage forms known to the Secretary to       be used in sunscreens marketed in the United States without a       new drug application approved under section 505 of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), the       Secretary shall submit a report to the Committee on Energy       and Commerce of the House of Representatives and the       Committee on Health, Education, Labor, and Pensions of the       Senate on the rationale for omission of such provisions from       such order, and a plan and timeline to compile any       information necessary to address such provisions through such       order.        (d) Treatment of Non-sunscreen Time and Extent       Applications.--        (1) In general.--Any application described in section 586F       of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.       360fff-6) that was submitted to the Secretary pursuant to       section 330.14 of title 21, Code of Federal Regulations, as       such provisions were in effect immediately prior to the date       of enactment date of this Act, shall be extinguished as of       such date of enactment, subject to paragraph (2).        (2) Order request.--Nothing in paragraph (1) precludes the       submission of an order request under section 505G(b) of the       Federal Food, Drug, and Cosmetic Act, as added by section       1001 of this Act, with respect to a drug that was the subject       of an application extinguished under paragraph (1).       SEC. 1005. ANNUAL UPDATE TO CONGRESS ON APPROPRIATE PEDIATRIC                     INDICATION FOR CERTAIN OTC COUGH AND COLD                     DRUGS.         (a) In General.--Subject to subsection (c), the Secretary       of Health and Human Services shall, beginning not later than       1 year after the date of enactment of this Act, annually       submit to the Committee on Energy and Commerce of the House       of Representatives and the Committee on Health, Education,       Labor, and Pensions of the Senate a letter describing the       progress of the Food and Drug Administration--        (1) in evaluating the cough and cold monograph described in       subsection (b) with respect to children under age 6; and        (2) as appropriate, revising such cough and cold monograph       to address such children through the order process under       section 505G(b) of the Federal Food, Drug, and Cosmetic Act,       as added by section 1001 of this Act.        (b) Cough and Cold Monograph Described.--The cough and cold       monograph described in this subsection consists of the       conditions under which nonprescription drugs containing       antitussive, expectorant, nasal decongestant, or       antihistamine active ingredients (or combinations thereof)       are generally recognized as safe and effective, as specified       in part 341 of title 21, Code of Federal Regulations (as in       effect immediately prior to the date of enactment of this       Act), and included in an order deemed to be established under       section 505G(b) of the Federal Food, Drug, and Cosmetic Act,       as added by section 1001 of this Act.        (c) Duration of Authority.--The requirement under       subsection (a) shall terminate as of the date of a letter       submitted by the Secretary of Health and Human Services       pursuant to such subsection in which the Secretary indicates       that the Food and Drug Administration has completed its       evaluation and revised, in a final order, as applicable, the       cough and cold monograph as described in subsection (a)(2).       SEC. 1006. TECHNICAL CORRECTIONS.         (a) Imports and Exports.--Section 801(e)(4)(E)(iii) of the       Federal Food, Drug, and Cosmetic Act (21 U.S.C.       381(e)(4)(E)(iii)) is amended by striking ``subparagraph''       each place such term appears and inserting ``paragraph''.        (b) FDA Reauthorization Act of 2017.--        (1) In general.--Section 905(b)(4) of the FDA       Reauthorization Act of 2017 (Public Law115-52) is amended by       striking ``Section 744H(e)(2)(B)'' and inserting ``Section       744H(f)(2)(B)''.        (2) Effective date.--The amendment made by paragraph (1)       shall take effect as of the enactment of the FDA       Reauthorization Act of 2017 (Public Law 115-52).  [[Page H10389]]                                 TITLE II--USER FEES       SEC. 2001. SHORT TITLE; FINDING.         (a) Short Title.--This title may be cited as the ``Over-      the-Counter Monograph User Fee Act of 2018''.        (b) Finding.--The Congress finds that the fees authorized       by the amendments made in this title will be dedicated to OTC       monograph drug activities, as set forth in the goals       identified for purposes of part 10 of subchapter C of chapter       VII of the Federal Food, Drug, and Cosmetic Act, in the       letters from the Secretary of Health and Human Services to       the Chairman of the Committee on Health, Education, Labor,       and Pensions of the Senate and the Chairman of the Committee       on Energy and Commerce of the House of Representatives, as       set forth in the Congressional Record.       SEC. 2002. FEES RELATING TO OVER-THE-COUNTER DRUGS.         Subchapter C of chapter VII of the Federal Food, Drug, and       Cosmetic Act (21 U.S.C. 379f et seq.) is amended by inserting       after part 9 the following:             ``PART 10--FEES RELATING TO OVER-THE-COUNTER DRUGS       ``SEC. 744L. DEFINITIONS.         ``In this part:        ``(1) The term `affiliate' means a business entity that has       a relationship with a second business entity if, directly or       indirectly--        ``(A) one business entity controls, or has the power to       control, the other business entity; or        ``(B) a third party controls, or has power to control, both       of the business entities.        ``(2) The term `contract manufacturing organization       facility' means an OTC monograph drug facility where neither       the owner of such manufacturing facility nor any affiliate of       such owner or facility sells the OTC monograph drug produced       at such facility directly to wholesalers, retailers, or       consumers in the United States.        ``(3) The term `costs of resources allocated for OTC       monograph drug activities' means the expenses in connection       with OTC monograph drug activities for--        ``(A) officers and employees of the Food and Drug       Administration, contractors of the Food and Drug       Administration, advisory committees, and costs related to       such officers, employees, and committees and costs related to       contracts with such contractors;        ``(B) management of information, and the acquisition,       maintenance, and repair of computer resources;        ``(C) leasing, maintenance, renovation, and repair of       facilities and acquisition, maintenance, and repair of       fixtures, furniture, scientific equipment, and other       necessary materials and supplies; and        ``(D) collecting fees under section 744M and accounting for       resources allocated for OTC monograph drug activities.        ``(4) The term `FDA establishment identifier' is the unique       number automatically generated by Food and Drug       Administration's Field Accomplishments and Compliance       Tracking System (FACTS) (or any successor system).        ``(5) The term `OTC monograph drug' means a nonprescription       drug without an approved new drug application which is       governed by the provisions of section 505G.        ``(6) The term `OTC monograph drug activities' means       activities of the Secretary associated with OTC monograph       drugs and inspection of facilities associated with such       products, including the following activities:        ``(A) The activities necessary for review and evaluation of       OTC monographs and OTC monograph order requests, including--        ``(i) orders proposing or finalizing applicable conditions       of use for OTC monograph drugs;        ``(ii) orders affecting status regarding general       recognition of safety and effectiveness of an OTC monograph       ingredient or combination of ingredients under specified       conditions of use;        ``(iii) all OTC monograph drug development and review       activities, including intra-agency collaboration;        ``(iv) regulation and policy development activities related       to OTC monograph drugs;        ``(v) development of product standards for products subject       to review and evaluation;        ``(vi) meetings referred to in section 505G(i);        ``(vii) review of labeling prior to issuance of orders       related to OTC monograph drugs or conditions of use; and        ``(viii) regulatory science activities related to OTC       monograph drugs.        ``(B) Inspections related to OTC monograph drugs.        ``(C) Monitoring of clinical and other research conducted       in connection with OTC monograph drugs.        ``(D) Safety activities with respect to OTC monograph       drugs, including--        ``(i) collecting, developing, and reviewing safety       information on OTC monograph drugs, including adverse event       reports;        ``(ii) developing and using improved adverse event data-      collection systems, including information technology systems;       and        ``(iii) developing and using improved analytical tools to       assess potential safety risks, including access to external       databases.        ``(E) Other activities necessary for implementation of       section 505G.        ``(7) The term `OTC monograph order request' means a       request for an order submitted under section 505G(b)(5).        ``(8) The term `Tier 1 OTC monograph order request' means       any OTC monograph order request not determined to be a Tier 2       OTC monograph order request.        ``(9)(A) The term `Tier 2 OTC monograph order request'       means, subject to subparagraph (B), an OTC monograph order       request for--        ``(i) the reordering of existing information in the drug       facts label of an OTC monograph drug;        ``(ii) the addition of information to the other information       section of the drug facts label of an OTC monograph drug, as       limited by section 201.66(c)(7) of title 21, Code of Federal       Regulations (or any successor regulations);        ``(iii) modification to the directions for use section of       the drug facts label of an OTC monograph drug, if such       changes conform to changes made pursuant to section       505G(c)(3)(A);        ``(iv) the standardization of the concentration or dose of       a specific finalized ingredient within a particular finalized       monograph;        ``(v) a change to ingredient nomenclature to align with       nomenclature of a standards-setting organization; or        ``(vi) addition of an interchangeable term in accordance       with section 330.1 of title 21, Code of Federal Regulations       (or any successor regulations).        ``(B) The Secretary may, based on program implementation       experience or other factors found appropriate by the       Secretary, characterize any OTC monograph order request as a       Tier 2 OTC monograph order request (including       recharacterizing a request from Tier 1 to Tier 2) and publish       such determination in a proposed order issued pursuant to       section 505G.        ``(10)(A) The term `OTC monograph drug facility' means a       foreign or domestic business or other entity that--        ``(i) is--        ``(I) under one management, either direct or indirect; and        ``(II) at one geographic location or address engaged in       manufacturing or processing the finished dosage form of an       OTC monograph drug;        ``(ii) includes a finished dosage form manufacturer       facility in a contractual relationship with the sponsor of       one or more OTC monograph drugs to manufacture or process       such drugs; and        ``(iii) does not include a business or other entity whose       only manufacturing or processing activities are one or more       of the following: production of clinical research supplies,       testing, or placement of outer packaging on packages       containing multiple products, for such purposes as creating       multipacks, when each monograph drug product contained within       the overpackaging is already in a final packaged form prior       to placement in the outer overpackaging.        ``(B) For purposes of subparagraph (A)(i)(II), separate       buildings or locations within close proximity are considered       to be at one geographic location or address if the activities       conducted in such buildings or locations are--        ``(i) closely related to the same business enterprise;        ``(ii) under the supervision of the same local management;       and        ``(iii) under a single FDA establishment identifier and       capable of being inspected by the Food and Drug       Administration during a single inspection.        ``(C) If a business or other entity would meet criteria       specified in subparagraph (A), but for being under multiple       management, the business or other entity is deemed to       constitute multiple facilities, one per management entity,       for purposes of this paragraph.        ``(11) The term `OTC monograph drug meeting' means any       meeting regarding the content of a proposed OTC monograph       order request.        ``(12) The term `person' includes an affiliate of a person.        ``(13) The terms `requestor' and `sponsor' have the       meanings given such terms in section 505G.       ``SEC. 744 Mr. Speaker, I ask unanimous consent that all Members  have 5 legislative days in which to revise and extend their remarks and  insert extraneous materials in the Record on the bill.    Mr. Speaker, I yield myself such time as I may consume.   H.R. 7328 includes both the Pandemic and All-Hazards Preparedness Act  and the Over-the-Counter Monograph reform language. Both of these bills  have passed this House separately, and this today in front of us  includes bipartisan, bicameral agreements on these programs. Passage of  this bill is critical to our national security; and on this 100-year  anniversary of the Spanish flu, I can think of no more appropriate  piece of legislation to be considering.   I urge all Members to support the bill, and I yield back the balance  of my time.   